[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 317
1. Vishnevsiĭ EL, Loran OB, Saenko VS: [Sympathic hyperactivity and reservoir function of the bladder in men]. Urologiia; 2010 Sep-Oct;(5):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group 2 patients (n = 23) with prostatic adenoma have undergone uroflowmetric monitoring before and after treatment with doxasozine (640 uroflowgrams).
  • It may be a humoral process mediated by vasoconstriction and disorder of vesical blood flow.
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Aged. Aged, 80 and over. Heart Rate / drug effects. Humans. Male. Middle Aged. Organ Size / drug effects. Prostatic Hyperplasia / drug therapy. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / physiopathology

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21254643.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


2. Danilov VV, Elisseva EV, Vasil'chenko AV: [Tadenan treatment of prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):68, 70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tadenan treatment of prostatic adenoma].
  • Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526878.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Fatty Alcohols; 0 / Plant Extracts; 0 / Tadenan
  •  go-up   go-down


3. Bachmann A: Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):435-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2008 Aug;54(2):427-37 [18069117.001]
  • (PMID = 18069122.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


Advertisement
4. Gorilkovskiĭ LM, Zingerenko MB: [Efficacy and safety of tulosine in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):60, 62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of tulosine in patients with prostatic adenoma].
  • The study of tulosine (tamsulosine) efficacy and safety was made in 92 patients with lower urinary tract symptoms (LUTS) due to prostatic adenoma (PA).
  • Ultrasound investigation found no significant changes in the adenoma size.
  • Thus, tulosine is a safe and effective drug for treatment of prostatic adenoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Sulfonamides / adverse effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526876.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


5. Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, Hawk E, Pinsky PF: A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol; 2009 May;7(5):568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Aberrant crypt foci (ACF) are the putative precursor of colorectal adenomas.
  • METHODS: Subjects from the Prostate, Lung, Colorectal and Ovarian cancer screening trial were recruited for an ACF study, with subjects with adenoma history being oversampled.
  • RESULTS: A total of 505 (66% male; 55% > or =70 y) subjects from 4 institutions were examined; 42% had no adenoma, 32% had nonadvanced distal adenoma, and 25% had advanced distal adenoma at the baseline Prostate, Lung, Colorectal and Ovarian cancer screening trial examination (8.2 years before ACF examination on average).
  • Baseline adenoma status was not associated with ACF prevalence (range, 66%-69%) or mean number of ACF (range, 3.1-3.5).
  • CONCLUSIONS: ACF prevalence and number were not associated with adenoma history, and only 68.5% of endoscopic ACF were confirmed histologically.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418605.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01-CN2551
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


6. Chakravarti B, Dwivedi SK, Mithal A, Chattopadhyay N: Calcium-sensing receptor in cancer: good cop or bad cop? Endocrine; 2009 Jun;35(3):271-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One situation is loss of CaR expression, resulting in loss of growth suppressing effects of elevated extracellular Ca(2+) by CaR, reported in parathyroid adenoma and in colon carcinoma.
  • CaR signaling and effects have been studied in several cancers including ovarian cancers, gastrinomas, and gliomas in addition to comparatively detailed studies in breast, prostate, and colon cancers.
  • Pharmacological agonists and antagonists of CaR hold therapeutic promise depending on whether activation of CaR is required such as in case of colon cancer or inactivating the receptor is required as in the case of breast- and prostate tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10330-4 [9294210.001]
  • [Cites] Am J Obstet Gynecol. 1998 Feb;178(2):305-13 [9500491.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):598-608 [14966569.001]
  • [Cites] N Engl J Med. 1985 Feb 21;312(8):474-83 [3881673.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7553-7 [10713061.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1293-4; author reply 1295 [15026815.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):779-84 [12548575.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1267-74 [11701443.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1724-6 [8467485.001]
  • [Cites] Endocrinology. 2003 Dec;144(12):5188-93 [12970167.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1319-23 [8958305.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):698-714 [8969974.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4455-64 [12970324.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Bone. 2004 Sep;35(3):664-72 [15336602.001]
  • [Cites] Breast. 2004 Dec;13 Suppl 1:S19-28 [15585379.001]
  • [Cites] Acta Neuropathol. 1986;70(1):17-21 [3727931.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Sep;35(9):631-8 [7566395.001]
  • [Cites] Metabolism. 1984 Jan;33(1):50-3 [6690886.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2057-66 [10595935.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):587-93 [2167004.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Nat Med. 2002 Jan;8(1):35-40 [11786904.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2006 Aug;50(4):685-93 [17117294.001]
  • [Cites] Curr Osteoporos Rep. 2007 Sep;5(3):120-7 [17925193.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):779-86 [12632068.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):217-28 [15200145.001]
  • [Cites] N Engl J Med. 1997 Nov 20;337(21):1506-10 [9366582.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):496-502 [10507776.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4789-94 [11134144.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2092-102 [11697806.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1149-55 [10837003.001]
  • [Cites] Tidsskr Nor Laegeforen. 1992 Aug 10;112(18):2346-8 [1329263.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34871-9 [11390379.001]
  • [Cites] Cell Biochem Biophys. 2000;33(1):63-95 [11322513.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1389-94 [9769374.001]
  • [Cites] J Cell Biol. 2002 Jul 22;158(2):221-6 [12119356.001]
  • [Cites] Exp Cell Res. 2005 Aug 15;308(2):439-45 [15950968.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17 Suppl 2:N141-5 [12412791.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):169-80 [16025223.001]
  • [Cites] J Urol. 1996 Nov;156(5):1691-5 [8863572.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E435-42 [12388158.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1996 Jul;5(4):307-15 [8823527.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1114-20 [9422777.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):220-30 [16281261.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Ann N Y Acad Sci. 1999;889:120-7 [10668488.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Mar;56(3):243-54 [9056538.001]
  • [Cites] Hum Pathol. 1982 May;13(5):454-8 [6281168.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1111-9 [15067332.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s [17062703.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):615-8 [10543980.001]
  • [Cites] Prostate. 1997 May 15;31(3):168-74 [9167768.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):61-70 [12746564.001]
  • [Cites] J Physiol. 1998 Dec 1;513 ( Pt 2):411-24 [9806992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(13):4857-60 [3387442.001]
  • [Cites] J Lab Clin Med. 1994 Apr;123(4):547-55 [8145003.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2144-54 [15735754.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):281-304 [9633841.001]
  • [Cites] Endocrinology. 2002 Feb;143(2):596-606 [11796515.001]
  • [Cites] J Musculoskelet Neuronal Interact. 2004 Sep;4(3):308-18 [15615499.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9 [12679445.001]
  • [Cites] J Comp Neurol. 1986 May 15;247(3):275-96 [3522658.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7 [17804294.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):149-56 [11902565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13566-71 [15347804.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3812-8 [12097294.001]
  • [Cites] In Vitro Cell Dev Biol. 1989 Jul;25(7):643-9 [2753852.001]
  • [Cites] Glia. 1996 May;17(1):39-51 [8723841.001]
  • [Cites] J Cell Biol. 2004 Mar 1;164(5):769-79 [14993236.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1312-7 [8636323.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Feb;280(2):F291-302 [11208605.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:781-810 [15473860.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 May;290(5):E761-70 [16603723.001]
  • [Cites] Ther Apher Dial. 2005 Aug;9 Suppl 1:S27-34 [16109139.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1588-93 [9837810.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5031-6 [11016624.001]
  • [Cites] Glia. 1999 Mar;26(1):64-72 [10088673.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Jan;34(1):1-10 [17220661.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):148-58 [14699496.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):18-23 [18307015.001]
  • [Cites] J Cell Biochem. 1991 Jul;46(3):250-4 [1774225.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36865-75 [15215241.001]
  • [Cites] Semin Oncol. 1991 Jun;18(3):177-85 [2042059.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):510-8 [7967506.001]
  • [Cites] Science. 1986 Oct 10;234(4773):161-6 [3018928.001]
  • [Cites] Hum Mutat. 2000 Oct;16(4):281-96 [11013439.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6258s-6263s [17062710.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):318-29 [15647826.001]
  • [Cites] Mol Genet Metab. 1999 Oct;68(2):328-31 [10527684.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606 [8636374.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):991-9 [14647423.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15771-81 [1874734.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):389-94 [7493018.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] N Engl J Med. 1986 Apr 24;314(17):1094-101 [2870434.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):177-83 [10209148.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Mar;56(3):572-81 [6822654.001]
  • [Cites] Endocrinology. 1991 Jun;128(6):2999-3004 [2036974.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Sep;279(3):C691-9 [10942719.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Dec 13;299(4):532-8 [12459170.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):219-27 [2788697.001]
  • [Cites] EMBO J. 2006 Jul 12;25(13):2978-88 [16763551.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9065-73 [16982748.001]
  • [Cites] Clin Calcium. 2008 Jan;18(1):32-6 [18175869.001]
  • [Cites] Cytometry. 1996 May 1;24(1):64-73 [8723904.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):3982-7 [6162540.001]
  • [Cites] J Comput Assist Tomogr. 1992 Nov-Dec;16(6):856-9 [1385498.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2482-9 [15059902.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] J Neurosci Res. 1997 Apr 15;48(2):122-7 [9130140.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E329-37 [12700162.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):403-11 [12656660.001]
  • [Cites] Growth Factors. 2005 Jun;23(2):117-23 [16019433.001]
  • [Cites] Prostate. 2001 May 15;47(3):212-21 [11351351.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:353-61 [11085928.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1455-62 [17557293.001]
  • [Cites] Am J Respir Cell Mol Biol. 1994 Dec;11(6):701-6 [7946399.001]
  • [Cites] Diabetes. 2000 Mar;49(3):409-17 [10868962.001]
  • [Cites] J Biol Chem. 1995 May 26;270(21):12919-25 [7759551.001]
  • [Cites] J Bone Miner Res. 1999 Jun;14(6):878-82 [10352095.001]
  • [Cites] Endocrinology. 1986 Nov;119(5):2284-9 [3464413.001]
  • [Cites] Endocrinology. 2000 May;141(5):1882-92 [10803599.001]
  • [Cites] J Biol Chem. 1998 Aug 14;273(33):21267-75 [9694886.001]
  • [Cites] Biochem J. 1986 Sep 15;238(3):905-12 [2432886.001]
  • [Cites] Acta Diabetol Lat. 1979 Jan-Mar;16(1):9-18 [377879.001]
  • [Cites] Cancer Treat Rev. 2003 Jun;29(3):189-98 [12787713.001]
  • [Cites] News Physiol Sci. 2002 Apr;17:62-7 [11909994.001]
  • [Cites] J Histochem Cytochem. 2000 May;48(5):595-602 [10769043.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Mar;52(3):339-48 [10718832.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):245-89 [11773614.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24571-8 [11964407.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1727-36 [15637291.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):409-16 [11809689.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3481-6 [9329389.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):718-29 [14991763.001]
  • [Cites] Eur J Endocrinol. 2000 May;142(5):500-5 [10802529.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1206-13 [15657090.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):245-51 [12507303.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:695-723 [15473857.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1035-43 [17914073.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):899-908 [12952940.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):40-4 [17188489.001]
  • [Cites] Brain Res. 1999 Dec 18;851(1-2):116-24 [10642834.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Jul;45(1):105-13 [874057.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 23;320(2):455-60 [15219850.001]
  • [Cites] Bone. 2004 Aug;35(2):479-88 [15268900.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):48-54 [7942181.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):239-297 [11152759.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10439-48 [17079465.001]
  • [Cites] Breast Cancer. 1999 Oct 25;6(4):292-297 [11091732.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):511-5 [16564154.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G403-11 [17463182.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):703-7 [9467597.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10173-83 [10187801.001]
  • [Cites] Clin Breast Cancer. 2005 Feb;5 Suppl(2):S46-53 [15807924.001]
  • [Cites] Support Care Cancer. 2007 Nov;15(11):1243-9 [17393190.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2620-8 [9006895.001]
  • [Cites] Exp Cell Res. 2000 Jul 10;258(1):1-11 [10912782.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2908-16 [10342884.001]
  • [Cites] Front Biosci. 2003 May 01;8:s377-90 [12700051.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Mar 16;269(2):427-32 [10708570.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7839-49 [12420221.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1753-60 [10749150.001]
  • [Cites] J Bone Miner Res. 1989 Dec;4(6):839-44 [2610020.001]
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):88-96 [9011580.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4357-64 [11108243.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] Neuroepidemiology. 1990;9(1):2-16 [2330068.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] J Natl Med Assoc. 2007 Jan;99(1):35-45 [17304967.001]
  • [Cites] Endocrinology. 2004 Mar;145(3):1211-7 [14645111.001]
  • [Cites] Nihon Rinsho. 1998 Jun;56(6):1419-24 [9648458.001]
  • [Cites] Br J Urol. 1996 Jan;77(1):102-6 [8653278.001]
  • [Cites] In Vitro. 1984 Aug;20(8):652-62 [6500605.001]
  • [Cites] Endocrinology. 1993 Apr;132(4):1658-64 [8462465.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):725-51 [11787845.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17(7):1164-70 [12096830.001]
  • [Cites] Biochem Biophys Res Commun. 1975 Nov 17;67(2):525-9 [812497.001]
  • [Cites] Subcell Biochem. 2007;45:405-27 [18193646.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 6:vi164-7 [17591815.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):355-60 [15225800.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34880-7 [11390380.001]
  • [Cites] Hosp Pract (Off Ed). 1992 Nov 15;27(11):51-8 [1331139.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):589-602 [17786953.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):229-37 [15200146.001]
  • [Cites] J Bone Miner Res. 2003 Dec;18(12):2200-5 [14672355.001]
  • (PMID = 19011996.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcium-Sensing
  • [Number-of-references] 203
  •  go-up   go-down


7. Józsa LG: Histologic diagnoses of tissues from two nineteenth century Habsburgs. Paleopathol Newsl; 2008 Mar;(141):12-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gout (urate nephropathy), severe arteriosclerosis, prostate adenoma and purulent prostatitis could also be diagnosed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831390.001).
  • [ISSN] 0148-4737
  • [Journal-full-title] Paleopathology newsletter
  • [ISO-abbreviation] Paleopathol Newsl
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] United States
  • [Personal-name-as-subject] Habsburg J; Romanova AP
  •  go-up   go-down


8. Erdman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG, Schauer DB: CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res; 2005 May 15;65(10):3998-4004
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that addition of CD4+CD25+ lymphocytes in ApcMin/+ mice reduces multiplicity of epithelial adenomas.
  • Similarities with cancer of the breast, prostate, lung, and other sites raise the possibility of broader roles for regulatory lymphocytes in prevention and treatment of epithelial cancers in humans.
  • [MeSH-major] Adenoma / immunology. Adenoma / prevention & control. CD4-Positive T-Lymphocytes / immunology. Immunotherapy, Adoptive / methods. Intestinal Neoplasms / immunology. Intestinal Neoplasms / prevention & control

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899788.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA26731; United States / NIDDK NIH HHS / DK / R01 DK52413; United States / NIAID NIH HHS / AI / R01AI51404; United States / NCI NIH HHS / CA / R01CA67529; United States / NCRR NIH HHS / RR / T32RR07036
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 82115-62-6 / Interferon-gamma; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


9. Morozov AP, Trapeznikov MF, Kushlinskiĭ NE: [Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma]. Urologiia; 2007 Mar-Apr;(2):50-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma].
  • We compared serum levels of insulin-like growth factors (IGF) type 1 protein (IGFP-1) in prostatic cancer (PC) and prostatic adenoma (PA).
  • Sensitivity and specificity of IGFP-1 estimation for differential diagnosis of PC were 72.1 and 57.1%, respectively), of IGFP-1/PSA for differential diagnosis was 81.3 and 87.5%, respectively.
  • [MeSH-major] Biomarkers, Tumor / blood. Insulin-Like Growth Factor Binding Protein 1 / blood. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580387.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 1; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


10. Shaplygin LV, Sivakov AA: [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 May-Jun;(3):35-7, 39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis].
  • A conservative therapy with cernilton was given to 72 patients with chronic prostatitis and prostatic adenoma of stage I-II.
  • Detailed urologic examination before the treatment and after it demonstrates that cernilton is effective, safe and well tolerated medicine for prostatic adenoma and chronic prostatitis.
  • Cernilton is recommended for wider use in the treatment of patients with prostatic adenoma and chronic prostatitis.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722618.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


11. Mazo EB, Krivoborodov GG, Sukhanov SV, Ivanov RV, Sereda EG: [Efficacy and safety of a new dosage form of vitaprost (tablets coated with intestinally soluble cover) in patients with prostatic adenoma]. Urologiia; 2007 Nov-Dec;(6):55, 57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of a new dosage form of vitaprost (tablets coated with intestinally soluble cover) in patients with prostatic adenoma].
  • An active substance of the drug vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostatic gland.
  • The prostatic extract has an organ-tropic action in relation to the prostate: inhibits proliferative activity of the cells leading to suppression of prostatic adenoma development, reduces edema and activity of inflammation in prostatic diseases.
  • The new vitaprost tablets can decrease volume of the prostate (this trend was not significant), relieve infravesical obstruction and irritation, improve quality of life.
  • Vitaprost tablets coated with intestinally soluble cover are recommended as a component of combined treatment of prostatic adenoma in patients with moderate infravesical obstruction irrespective of the patients' age and concomitant diseases.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649662.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Tablets, Enteric-Coated; 0 / Vitaprost
  •  go-up   go-down


12. Krivoborodov GG, Mazo EB, Efremov NS: [Temporary stent--CoreFlow Soft Stent--for diagnosis of the causes of incomplete bladder emptying in men with neurological diseases]. Urologiia; 2009 Jan-Feb;(1):13-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temporary stent--CoreFlow Soft Stent--for diagnosis of the causes of incomplete bladder emptying in men with neurological diseases].
  • The new device--CoreFlow Soft Stent--was used for diagnosis of causes of incomplete bladder emptying (IBE) in 19 men with neurogenic diseases.
  • Group 1 consisted of 8 men with IBE and prostatic adenoma.
  • Group 2 consisted of 11 men with IBE but no prostatic adenoma.
  • Different active lengths of the stent are available to match it to the length of the prostatic urethra.
  • The introducer part was then separated from the stent part positioned in the prostatic urethra.
  • Out of 8 patients with prostatic adenoma and neurogenic diseases 4 could urinate with the stent part positioned in the prostatic urethra indicating that prostatic adenoma was the cause for IBE.
  • Our experience indicates that CoreFlow Soft Stent is a simple device for diagnosis of the causes of IBE in men with neurogenic diseases.
  • [MeSH-major] Stents. Urinary Bladder, Neurogenic / diagnosis. Urinary Retention / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432228.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


13. Stravodimos KG, Petrolekas A, Kapetanakis T, Vourekas S, Koritsiadis G, Adamakis I, Mitropoulos D, Constantinides C: TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? Int Urol Nephrol; 2009 Dec;41(4):767-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up?
  • This tactic however might not be optimum since data exist on the superiority of TRUS over transabdominal ultrasound in accurately predicting prostate volumes.
  • We aimed to evaluate TRUS as a standard tool in the evaluation of patients with benign prostate hyperplasia (BPH) with a special focus on the potential impact it might have on the decision of open versus transurethral surgery.
  • PATIENTS AND METHODS: Seventy-one patients presenting with LUTS due to BPH and eventually managed with open surgery based on their preference and prostate volume were included in the protocol.
  • These were compared with respective transabdominal calculations of the prostate volume as well as the enucleated specimen weight (W).
  • CONCLUSION: TRUS is more accurate than transabdominal ultrasound in predicting adenoma volume in patients with BPH and its standard use might lead to fewer open approaches, with consequent less morbidity and hospitalization.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Hyperplasia / diagnostic imaging. Ultrasound, High-Intensity Focused, Transrectal / methods. Urinary Tract Infections / diagnosis
  • [MeSH-minor] Abdomen / diagnostic imaging. Adenoma / diagnostic imaging. Aged. Aged, 80 and over. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Organ Size. Predictive Value of Tests. Preoperative Care / methods. Preoperative Care / standards. Probability. Prostatic Neoplasms / diagnostic imaging. Regression Analysis. Risk Assessment. Sensitivity and Specificity. Severity of Illness Index. Treatment Outcome. Ultrasonography, Doppler / methods


14. Miller AM, Iaroshenko VP, Soroka PV, Stakhnev EIu: [Efficacy of vitaprost forte in patients with prostatic adenoma]. Urologiia; 2008 Sep-Oct;(5):50, 52-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in patients with prostatic adenoma].
  • The trial of a new bioregulatory peptide vitaprost forte (100 mg rectal suppositoria) in 30 patients with prostatic adenoma demonstrated that this drug attenuates clinical symptoms of the disease, improves quality of life, uroflowmetric parameters and reduces size of the prostate.
  • Vitaprost forte is more effective in patients with prostatic adenoma in combination with chronic prostatitis, has antiaggregant and anticoagulant properties, stimulates synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostate resulting in regressioin of edema, activity of inflammation in prostatic diseases.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069497.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


15. Tarasov NI, Izmaĭlov RI: [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride]. Urologiia; 2009 Sep-Oct;(5):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride].
  • Combined treatment with doxasozine and finasteride was performed for 7.26 months in 38 patients with large-size prostatic adenoma (89.54 +/- 11.64 cm3).
  • The control group (28 patients with large prostatic adenoma) received surgical treatment alone.
  • Thus, combined treatment with doxasozine and finasteride can be the first-line treatment in patients with large prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatectomy. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209869.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


16. Wong-You-Cheong JJ, Woodward PJ, Manning MA, Davis CJ: From the archives of the AFIP: Inflammatory and nonneoplastic bladder masses: radiologic-pathologic correlation. Radiographics; 2006 Nov-Dec;26(6):1847-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephrogenic adenoma has no typical features, and pathologic evaluation is required for diagnosis.
  • The various types of cystitis (cystitis cystica, cystitis glandularis, and eosinophilic cystitis) require pathologic diagnosis.
  • The diagnosis of chemotherapy cystitis and radiation cystitis should be clinically evident, but imaging may be used to determine severity and to assess complications.
  • The extravesical findings allow the diagnosis to be made easily.
  • Finally, extrinsic masses arising from the prostate or distal ureter may cause filling defects, which can be confused with intrinsic bladder masses.
  • [MeSH-major] Image Enhancement / methods. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods. Urinary Bladder Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102055.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


17. Maksimov IB, Sergienko NF, Shchekochikhin AV, Deviatov AS, Baglaĭ GV: [The 20th anniversary of Urological Center of Main Military Clinical Hospital named after N. N. Burdenko]. Voen Med Zh; 2009 Sep;330(9):38-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent diseases--adenoma of prostate, malignant swelling and benign tumour of urological organs, urolithiasis, traumatic damages of urological organs.
  • [MeSH-minor] History, 20th Century. History, 21st Century. Humans. Male. Moscow. Prostatectomy / history. Prostatectomy / methods. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / history. Prostatic Hyperplasia / surgery. Urologic Diseases / diagnosis. Urologic Diseases / history. Urologic Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020614.001).
  • [ISSN] 0026-9050
  • [Journal-full-title] Voenno-medit︠s︡inskiĭ zhurnal
  • [ISO-abbreviation] Voen Med Zh
  • [Language] rus
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


18. Zhang Y, Du CJ, Xu G, Chen JM, Jing X: [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g]. Zhonghua Nan Ke Xue; 2007 Dec;13(12):1091-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g].
  • OBJECTIVE: To evaluate the effect of transurethral holmium laser enucleation of the prostate (HoLEP) for prostate adenoma greater than 100 g.
  • METHODS: Sixty BPH patients with the prostate larger than 100 g were randomized to two treatment groups of HoLEP (n = 32) and open prostatectomy (n = 28).
  • Comparisons were made between the two groups in operating time, blood loss, bladder irrigating time, catheterization time and hospital stay, as well as in the international prostate symptom score (IPSS), quality of life (QOL) score, maximum urinary flow rate (Qmax) and postvoid residual volume (PVR) before and 3 months after the surgery.
  • CONCLUSION: HoLEP and open prostatectomy are equally effective procedures for removal of large prostate adenomas, but the former is a better surgical option for prostate adenomas larger than 100 g for its greater safety, less pain and faster recovery.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284057.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] W1XX32SQN1 / Holmium
  •  go-up   go-down


19. Berndt SI, Huang WY, Fallin MD, Helzlsouer KJ, Platz EA, Weissfeld JL, Church TR, Welch R, Chanock SJ, Hayes RB: Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. Cancer Res; 2007 Feb 1;67(3):1395-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma.
  • To examine the relationship between genetic variation in BER genes and colorectal adenoma risk, we conducted a case-control study of 767 cases of advanced colorectal adenoma and 773 controls from the baseline screening exam of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
  • Cases included participants diagnosed with advanced left-sided adenoma, and controls were subjects without evidence of a left-sided polyp by sigmoidoscopy, frequency-matched to cases on race and gender.
  • Twenty single nucleotide polymorphisms were genotyped in four BER genes (APEX1, PARP1, POLB, and XRCC1), and conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for the association with colorectal adenoma.
  • The APEX1 51H variant was associated with a borderline significant decreased risk of colorectal adenoma (OR, 0.66; 95% CI, 0.44-1.00), and the XRCC1 399Q variant was inversely associated with risk among Caucasians (OR, 0.80; 95% CI, 0.64-0.99).
  • Homozygotes at two PARP1 loci (A284A and IVS13+118G>A) were also associated with a decreased risk of colorectal adenoma compared with wild-type carriers (OR, 0.70; 95% CI, 0.49-0.98 for both), which was restricted to advanced adenomas displaying histologically aggressive characteristics (OR, 0.51; 95% CI, 0.33-0.78, P = 0.002 for PARP1 A284A).
  • This study suggests that polymorphisms in APEX1, XRCC1, and PARP1 may be associated with advanced colorectal adenoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283177.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


20. Schoen RE, Weissfeld JL, Pinsky PF, Riley T: Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopy. Gastroenterology; 2006 Dec;131(6):1683-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopy.
  • To examine the yield at colonoscopy when a given size lesion is observed, we assessed the yield of advanced adenoma and cancer at colonoscopy based on the size of the abnormality detected at flexible sigmoidoscopy (FSG).
  • METHODS: We used data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a randomized, controlled, community-based study of FSG.
  • For women with a polyp 0.5-0.9 cm on FSG (n = 1426), the yield in the distal colon on colonoscopy was 0.6% for cancer (number needed to screen [NNS] = 166) and 14.5% for advanced adenoma (NNS = 7).
  • In men (n = 2183), the yield was 0.7% (NNS = 142) for cancer and 15.9% (NNS = 6) for advanced adenoma.
  • Among persons with polyps 0.5-0.9 cm identified on FSG, 5.5% (198/3609) had distal advanced adenomas that measured <1.0 cm but had villous histology or high-grade dysplasia, and 9.9% (357/3609) had adenomas > or =1 cm.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Sigmoidoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterology. 2006 Dec;131(6):2006-9 [17188963.001]
  • (PMID = 17188959.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN2551
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


21. Patriarca C, Zucchini N, Corrada P: Giant multilocular prostate cystoadenoma: an entirely benign prostate neoplasm with some phenotypic features of malignancy. Am J Surg Pathol; 2005 Sep;29(9):1252-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant multilocular prostate cystoadenoma: an entirely benign prostate neoplasm with some phenotypic features of malignancy.
  • [MeSH-major] Adenoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Racemases and Epimerases / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Surg Pathol. 2004 Jun;28(6):701-5 [15166661.001]
  • [CommentOn] Am J Surg Pathol. 2004 Sep;28(9):1224-9 [15316323.001]
  • (PMID = 16096417.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


22. Markov AV, Luk'ianov IV, Loran OB: [Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy]. Urologiia; 2007 Jul-Aug;(4):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy].
  • Rehabilitation therapy was performed in 5 groups (n=122) of patients operated for prostatic adenoma (TUR of the prostate, transvesical prostatectomy) and having postoperative marked irritative miction disorders.
  • Thus, adjuvant physiotherapy inclusion in the complex of postoperative rehabilitation of patients operated for prostatic adenoma is justified as it improves treatment efficacy.
  • [MeSH-major] Prostatic Hyperplasia / rehabilitation. Urinary Incontinence / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / methods. Follow-Up Studies. Humans. Male. Middle Aged. Prostate / surgery. Prostatectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915448.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


23. Kocarnik JD, Hutter CM, Slattery ML, Berndt SI, Hsu L, Duggan DJ, Muehling J, Caan BJ, Beresford SA, Rajkovic A, Sarto GE, Marshall JR, Hammad N, Wallace RB, Makar KW, Prentice RL, Potter JD, Hayes RB, Peters U: Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis. Cancer Epidemiol Biomarkers Prev; 2010 Dec;19(12):3131-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis.
  • We included Caucasians with colorectal adenoma or colorectal cancer and controls from 4 studies (total 3,891 cases, 4,490 controls): the Women's Health Initiative (WHI); the Diet, Activity and Lifestyle Study (DALS); a Minnesota population-based case-control study (MinnCCS); and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO).
  • RESULTS: SNP rs719725 was statistically significantly associated with risk of colorectal cancer in WHI (OR per A allele 1.19; 95% CI, 1.01-1.40; P(trend) = 0.04), marginally associated with adenoma risk in PLCO (OR per A allele 1.11; 95% CI, 0.99-1.25; P(trend) = 0.07), and not associated in DALS and MinnCCS.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):616-21 [19155440.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):629-34 [9310563.001]
  • [Cites] Nat Rev Genet. 2009 Jun;10(6):353-8 [19434079.001]
  • [Cites] Hum Mol Genet. 2008 Sep 1;17(17):2665-72 [18535017.001]
  • [Cites] Cancer Res. 1997 Jan 1;57(1):75-80 [8988044.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):779-84 [8896888.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 [15358723.001]
  • [Cites] Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21 [14575943.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Stat Med. 2001 Jul 30;20(14):2115-30 [11439425.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):887-92 [18004301.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11128-32 [18056436.001]
  • [Cites] PLoS One. 2007;2(9):e841 [17786212.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):989-94 [17618283.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):882-4 [19561607.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • (PMID = 20978172.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA048998-12A2; United States / WHI NIH HHS / WH / N01 WH032112; United States / WHI NIH HHS / WH / N01 WH042122; United States / NCI NIH HHS / CA / R01 CA059045; United States / PHS HHS / / 32105-6; United States / WHI NIH HHS / WH / N01 WH32115; United States / WHI NIH HHS / WH / N01 WH042110; None / None / / N01 WH032102; United States / WHI NIH HHS / WH / N01WH22110; United States / WHI NIH HHS / WH / WH024152; United States / NIA NIH HHS / AG / R01 AG014358; United States / NIA NIH HHS / AG / R01 AG14358; United States / WHI NIH HHS / WH / N01 WH042114; United States / WHI NIH HHS / WH / N01 WH032105; United States / WHI NIH HHS / WH / N01 WH042107; United States / WHI NIH HHS / WH / N01 WH042126; United States / NCI NIH HHS / CA / P01 CA53996; United States / WHI NIH HHS / WH / N01 WH032109; United States / NCI NIH HHS / CA / P01 CA053996; United States / WHI NIH HHS / WH / N01 WH032102; None / None / / N01 WH044221; United States / WHI NIH HHS / WH / N01 WH042108-011; United States / NCI NIH HHS / CA / CA059045-05; United States / NIA NIH HHS / AG / AG014358-06; United States / PHS HHS / / 42107-26; United States / PHS HHS / / 32115; United States / WHI NIH HHS / WH / N01 WH022110; United States / WHI NIH HHS / WH / N01 WH042121; United States / WHI NIH HHS / WH / N01 WH032111; United States / WHI NIH HHS / WH / N01 WH032122; United States / NCI NIH HHS / CA / CA048998-12A2; United States / WHI NIH HHS / WH / N01 WH032118; United States / NCI NIH HHS / CA / R01 CA048998; United States / NCI NIH HHS / CA / K22 CA118421-01; United States / NCI NIH HHS / CA / R25 CA094880; United States / WHI NIH HHS / WH / N01 WH042130; United States / NIA NIH HHS / AG / R01 AG014358-06; United States / NCI NIH HHS / CA / U01 CA137088; United States / WHI NIH HHS / WH / N01 WH042115; United States / WHI NIH HHS / WH / N01 WH042131; United States / WHI NIH HHS / WH / N01 WH042119; None / None / / N01 WH032100; United States / NCI NIH HHS / CA / P01 CA053996-30; United States / WHI NIH HHS / WH / N01 WH042116; United States / PHS HHS / / 32100-2; United States / NCI NIH HHS / CA / CA118421-01; United States / PHS HHS / / 24152; United States / NCI NIH HHS / CA / R01 CA059045-05; United States / Intramural NIH HHS / / ; United States / WHI NIH HHS / WH / N01 WH042117; United States / NCI NIH HHS / CA / R01 CA48998; United States / PHS HHS / / 42129-32; United States / WHI NIH HHS / WH / N01 WH042109; United States / NIH HHS / OD / N01 WH42124; United States / NCI NIH HHS / CA / R25 CA094880-01; United States / WHI NIH HHS / WH / N01 WH032106; United States / PHS HHS / / 32118-32119; United States / WHI NIH HHS / WH / N01 WH042132; None / None / / N01 WH042113; United States / NCI NIH HHS / CA / CA053996-30; United States / WHI NIH HHS / WH / N01 WH032100; United States / PHS HHS / / 32108-9; United States / WHI NIH HHS / WH / N01 WH044221; United States / NCI NIH HHS / CA / K22 CA118421; United States / WHI NIH HHS / WH / N01 WH042112; United States / WHI NIH HHS / WH / N01 WH042125; United States / NCI NIH HHS / CA / R01 CA120582-01; United States / WHI NIH HHS / WH / N01 WH042111; United States / WHI NIH HHS / WH / N01 WH042113; United States / NCI NIH HHS / CA / CA120582-01; United States / PHS HHS / / 32122; United States / WHI NIH HHS / WH / N01 WH022110-024; United States / NCI NIH HHS / CA / R01 CA120582; United States / WHI NIH HHS / WH / N01 WH042120; United States / WHI NIH HHS / WH / N01 WH032108; United States / PHS HHS / / 44221; United States / PHS HHS / / 32111-13; United States / WHI NIH HHS / WH / N01 WH042123; United States / NCI NIH HHS / CA / CA094880-01; United States / WHI NIH HHS / WH / N01 WH032119; United States / WHI NIH HHS / WH / N01 WH042129; United States / WHI NIH HHS / WH / N01 WH032113; United States / WHI NIH HHS / WH / N01 WH024152
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS248201; NLM/ PMC3005543
  •  go-up   go-down


24. Hiripi E, Bermejo JL, Sundquist J, Hemminki K: Association of colorectal adenoma with other malignancies in Swedish families. Br J Cancer; 2008 Mar 11;98(5):997-1000
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of colorectal adenoma with other malignancies in Swedish families.
  • Using the Swedish Family-Cancer Database covering over 11.5 million individuals, estimated relative risks (RRs) for colorectal adenoma were using Poisson's regression.
  • The RR of colorectal adenoma was found to be increased among first-degree relatives of patients with colorectal cancer (2.72; 95% confidence interval=2.46-3.00) and among the offspring and siblings of patients with endometrial and prostate cancers.
  • We also found an increased risk of colorectal adenoma for the offspring of individuals with stomach cancer and leukaemia, and for siblings of those with pancreatic cancer and multiple myeloma.
  • Our results suggest that colorectal adenoma may share a genetic aetiology with cancer even at extracolorectal sites.
  • Increases of colorectal adenoma in families affected by prostate cancer and acute leukaemia cannot be attributed to known cancer syndromes, although the play of chance cannot be excluded.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1109-17 [10533456.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):304-8 [16477631.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3624-8 [11151903.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):294-8 [11410880.001]
  • [Cites] Mol Pathol. 2001 Aug;54(4):206-14 [11477132.001]
  • [Cites] Acta Oncol. 2001;40(6):772-7 [11765074.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):743-8 [11745471.001]
  • [Cites] Gut. 2002 Feb;50(2):228-34 [11788565.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Gut. 2003 May;52(5):747-51 [12692063.001]
  • [Cites] Gut. 2004 Sep;53(9):1322-8 [15306593.001]
  • [Cites] Int J Cancer. 1988 Apr 15;41(4):513-7 [3356486.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1618-26 [7932826.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):172-5 [9754648.001]
  • [Cites] Eur J Cancer. 2004 Nov;40(16):2480-7 [15519523.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s240-2 [15666098.001]
  • [Cites] Acta Oncol. 2005;44(5):425-39 [16118076.001]
  • [Cites] Semin Gastrointest Dis. 2000 Oct;11(4):176-84 [11057945.001]
  • (PMID = 18283306.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2266856
  •  go-up   go-down


25. Krambeck AE: Evolution and success of holmium laser enucleation of the prostate. Indian J Urol; 2010 Jul;26(3):404-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution and success of holmium laser enucleation of the prostate.
  • AIMS: The purpose of this article is to review the development of instruments, current technique, and expected outcomes for holmium laser enucleation of the prostate (HoLEP).
  • RESULTS: Historically, the gold-standard management for symptomatic obstructing benign prostatic hyperplasia (BPH) has been transurethral resection of the prostate (TURP).
  • Laser treatment of BPH has evolved from coagulation to complete adenoma enucleation.
  • The holmium laser was initially utilized for prostate ablation and soon evolved into holmium laser tissue resection, but was limited by difficulties with extracting the prostate tissue from the bladder.
  • With the development of a compatible tissue morcellator whole prostate lobes could be enucleated similar to an open prostate enucleation and the HoLEP procedure was developed.
  • Changes in enucleation technique have also increased the efficiency of the HoLEP procedure, such that any sized prostate can be treated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21116363.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2978443
  • [Keywords] NOTNLM ; Benign prostatic hyperplasia / holmium laser / prostate enucleation
  •  go-up   go-down


26. Traore CB, Kamate B, Toure ML, Diarra T, Bayo S: [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases]. Mali Med; 2006;21(4):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases].
  • [Transliterated title] Aspects anatomopathologiques, cliniques et radiologiques des tumeurs benignes de la prostate au Mali, a propos de 759 cas.
  • The benign prostate tumours are dominated by prostatic adenomyoma.
  • The objective of this work is to describe the anatomo-pathological, clinical and radiological aspects of benign prostate tumours in Mali.
  • It has involved 759 patients who had histological confirmed prostate adenoma in the Department of Urology in Point G University Hospital.
  • The patients were classified according to age, the clinical exam, the rate of prostate specific antigen (PSA), the sonogram, the macro and microscopic exam.
  • The apical part of the prostate is the area mostly involved.
  • "The night pollakiuria" was the primarily clinical sign in all patients; the prostate specific antigen (PSA) is high among more than 80%.
  • [MeSH-major] Adenomyoma / pathology. Adenomyoma / radiography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiography. Urology Department, Hospital / statistics & numerical data
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. Hospitals, University. Humans. Incidence. Male. Mali / epidemiology. Middle Aged. Prostate-Specific Antigen / blood. Retrospective Studies. Urination Disorders / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437843.001).
  • [ISSN] 0464-7874
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


27. Rasner PI, Pushkar' DIu: [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma].
  • Acute urinary retention in males is often caused by infravesical obstruction due to enlargement of the prostatic gland.
  • Recently it was found that alpha-adrenoblockers promote recovery of physiological voiding in patients with benign prostatic hyperplasia.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / therapy. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Urinary Catheterization. Urinary Retention / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. ALFUZOSIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169720.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Quinazolines; 0 / Sulfonamides; 90347YTW5F / alfuzosin; G3P28OML5I / tamsulosin
  •  go-up   go-down


28. Neĭmark AI, Isaenko VI, Iakovets IaV, Simashkevich AV, Aliev RT: [Administration of afala preparation in urological practice]. Urologiia; 2009 May-Jun;(3):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination.
  • Afala is indicated for prophylaxis in patients with initial stage of prostatic adenoma and as an alternative to expectation policy.
  • [MeSH-major] Antibodies / therapeutic use. Prostate / drug effects. Prostatic Hyperplasia / drug therapy. Urination Disorders / prevention & control
  • [MeSH-minor] Aged. Drug Administration Schedule. Humans. Male. Middle Aged. Organ Size / drug effects. Prostate-Specific Antigen / blood. Prostate-Specific Antigen / immunology. Quality of Life. Severity of Illness Index. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673125.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies; 0 / afala; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


29. Parma P, Dall'Oglio B, Samuelli A, Bondavalli C, Bellomi A: [Laparoscopic removal of voluminous right seminal vesicle neoplasm]. Urologia; 2010 Oct-Dec;77 Suppl 17:46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Asportazione laparoscopica di voluminosa neoplasia della vescicola seminale destra.
  • The diagnosis was achieved by transrectal ultrasound, CT of the abdomen and pelvis, and biopsy of both prostate and seminal vesicle.
  • [MeSH-minor] Adenoma / complications. Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Adnexal Diseases / complications. Adnexal Diseases / diagnosis. Adnexal Diseases / pathology. Adnexal Diseases / surgery. Biopsy. Diagnosis, Differential. Hemospermia / etiology. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Vas Deferens / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308675.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Wolffian tumor
  •  go-up   go-down


30. Hojgaard M, Mikines KJ: Ureteral injuries during photoselective vaporization of the prostate. Scand J Urol Nephrol; 2010 Sep;44(4):265-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteral injuries during photoselective vaporization of the prostate.
  • Photoselective vaporization of the prostate is a relatively new surgical modality for male lower urinary tract symptoms.
  • The method has a risk of tissue damage if laser pulses miss the prostatic adenoma and travel through the irrigation fluid in the bladder.
  • Five cases of damage to the ureteral orifices are described, with hidden orifices, intravesical prostatic adenomas and prior prostatectomy as risk factors for laser-related injuries to ureteral orifices.
  • [MeSH-major] Laser Therapy / adverse effects. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Ureter / injuries

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201751.001).
  • [ISSN] 1651-2065
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Wang MH, Lee W, Luo YL, Weis MT, Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol; 2007 Dec;213(4):402-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, limited RON overexpression was observed in cancers from stomach, kidney, brain, liver, ovary, and prostate.
  • Detailed analysis of thyroid tissues showed that RON was hardly detected in normal thyroid cells, moderately expressed in adenoma samples, but overexpressed in about half of papillary and follicular cancer specimens.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Pathological Society of Great Britain and Ireland
  • (PMID = 17955509.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA91980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Neoplasm Proteins; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


32. Gorilovskiĭ LM, Zingerenko MB, Lakhno DA: [Efficacy of setegis administration after transvesical adenomectomy]. Urologiia; 2007 Nov-Dec;(6):61, 63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prazosin / analogs & derivatives. Prostatic Hyperplasia / surgery. Urination / drug effects. Urination Disorders / drug therapy. Urologic Surgical Procedures, Male

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649663.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 8L5014XET7 / Terazosin; XM03YJ541D / Prazosin
  •  go-up   go-down


33. Mucha SA, Meleń-Mucha G, Godlewski A, Stepień H: Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Arch; 2007 Mar;450(3):335-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the significance of matrix metalloproteinases (MMPs) for tumor growth and angiogenesis, we have studied the effect of batimastat (BB-94), a synthetic MMPs inhibitor (MMPI) on the progression of prolactin-secreting pituitary adenoma in rats.
  • The ability of BB-94 to suppress established pituitary tumor growth suggests a possible application of MMPIs in the treatment of pituitary adenomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1999 Dec;45(6):1432-40; discussion 1440-1 [10598711.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2931-5 [10946906.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):359-64 [7893282.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5356-64 [10537320.001]
  • [Cites] Prostate. 1998 Jun 1;35(4):248-54 [9609547.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jul;81(14):4549-53 [6589610.001]
  • [Cites] Invest New Drugs. 1996;14(2):193-202 [8913840.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2087-91 [8347186.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Aug;7(2):120-5 [1497900.001]
  • [Cites] Nature. 1987 Apr 2-8;326(6112):515-7 [2882423.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Biol Reprod. 1999 Jan;60(1):176-82 [9858503.001]
  • [Cites] Endocr Pathol. 2000 Winter;11(4):341-352 [12114758.001]
  • [Cites] Drugs. 2000 May;59(5):1043-55 [10852638.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):263-9 [10634397.001]
  • [Cites] Endocrine. 1999 Dec;11(3):217-33 [10786818.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5A):3615-9 [9858948.001]
  • [Cites] Mol Cell Endocrinol. 1996 Nov 29;124(1-2):33-42 [9027322.001]
  • [Cites] FASEB J. 1991 May;5(8):2145-54 [1850705.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2528-33 [9059343.001]
  • [Cites] Am J Anat. 1987 Aug;179(4):315-23 [3661455.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):259-272 [12114787.001]
  • [Cites] Prostate. 2000 May 1;43(2):77-82 [10754522.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):45-53 [8690524.001]
  • [Cites] J Endocrinol. 1996 Jul;150(1):99-106 [8708569.001]
  • [Cites] J Natl Cancer Inst. 1995 Oct 18;87(20):1546-50 [7563189.001]
  • [Cites] J Surg Res. 1997 May;69(2):367-71 [9224409.001]
  • [Cites] Int J Cancer. 1995 Mar 29;61(1):27-34 [7705930.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):460-4 [8050828.001]
  • [Cites] Ann Oncol. 1995 Dec;6(10):967-74 [8750146.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):733-44 [3095506.001]
  • [Cites] Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):353-65 [10909428.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):500-9 [2760167.001]
  • [Cites] Cell Res. 1998 Sep;8(3):171-7 [9791730.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1089-94 [8496297.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):205-8 [8431353.001]
  • [Cites] Endocrinology. 1981 Nov;109(5):1700-7 [7297500.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 15;87(4):293-8 [7535861.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4726-8 [8062271.001]
  • [Cites] Neuroendocrinology. 1983 Jul;37(1):23-31 [6888657.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • (PMID = 17235567.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Estrogens; 0 / Proliferating Cell Nuclear Antigen; 0 / Protease Inhibitors; 0 / Thiophenes; 47E5O17Y3R / Phenylalanine; 731DCA35BT / Diethylstilbestrol; BK349F52C9 / batimastat; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


34. Sergienko NF, Vasil'chenko MI, Begaev AI, Shchekochikhin AV, Shershnev SP, Reĭniuk OL, Lototskiĭ MM: [Acute urinary retention in prostatic adenoma]. Urologiia; 2010 Jul-Aug;(4):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute urinary retention in prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Retention / etiology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Urinary Catheterization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973136.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


35. Shakhmachev VN: [Comparative evaluation of hemostatic methods during open adenomectomy]. Urologiia; 2010 Nov-Dec;(6):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The article compares effectiveness of different methods of hemostasis after transvesical adenomectomy for prostatic adenoma practiced in the world and presents original experience in surgical treatment of 224 patients with prostatic adenoma.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Hemostasis, Surgical / methods. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427988.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


36. Trapeznikova MF, Pozdniakov KV, Golubev GV, Terpigorev SA, Agel'tsov MV, Kuznetsov VE, Shvedov MIu: [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease]. Urologiia; 2009 Jan-Feb;(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease].
  • The aim of our study was assessment of clinical efficacy and safety of a new alpha-adrenoblocker kamiren XL in patients with prostatic adenoma (PA) with or without acute retention of urine (ARU).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434906.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


37. Bistulfi G, Vandette E, Matsui S, Smiraglia DJ: Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol; 2010 Jan 21;8:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells.
  • We recently demonstrated that sensitivity to low folate availability is affected by the rate of polyamine biosynthesis, which is prominent in prostate cells.
  • We, therefore, hypothesized that prostate cells might be highly susceptible to genetic, epigenetic and phenotypic changes consequent to folate restriction.
  • RESULTS: We studied the consequences of long-term, mild folate depletion in a model comprised of three syngenic cell lines derived from the transgenic adenoma of the mouse prostate (TRAMP) model, recapitulating different stages of prostate cancer; benign, transformed and metastatic.
  • High-performance liquid chromatography analysis demonstrated that mild folate depletion (100 nM) sufficed to induce imbalance in both the nucleotide and AdoMet pools in all prostate cell lines.
  • These genomic changes coincided with phenotype changes in the prostate cells including increased anchorage-independent growth and reduced sensitivity to folate depletion.
  • CONCLUSIONS: This study demonstrates that prostate cells are highly susceptible to genetic and epigenetic changes consequent to mild folate depletion as compared to cells grown with supraphysiological amounts of folate (2 microM) routinely used in tissue culture.
  • These results provide a strong rationale for studying the effects of folate manipulation on the prostate in vivo, where cells might be more sensitive to changes in folate status resulting from folate supplementation or antifolate therapeutic approaches.

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Jun 15;58(3):254-62 [10373323.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6872-80 [15286716.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):981-90 [15695236.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Mutat Res. 2006 Jan 29;593(1-2):80-7 [16144704.001]
  • [Cites] Gut. 2006 Oct;55(10):1387-9 [16966698.001]
  • [Cites] Genome Res. 2006 Oct;16(10):1222-30 [16954539.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10308-14 [17079450.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10349-56 [17079455.001]
  • [Cites] Exp Oncol. 2006 Sep;28(3):178-86 [17080009.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):216S-222S [17182829.001]
  • [Cites] Nat Rev Drug Discov. 2007 May;6(5):373-90 [17464296.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Sep;7(5):524-42 [17896913.001]
  • [Cites] Nucleic Acids Res. 2007;35(18):e119 [17855397.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1779(1):3-16 [18078840.001]
  • [Cites] BMC Genomics. 2007;8:446 [18053125.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Nutr Biochem. 2008 May;19(5):328-35 [17681772.001]
  • [Cites] J Natl Cancer Inst. 2009 Mar 18;101(6):432-5 [19276452.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2888-97 [19417083.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Nutr Cancer. 2000;37(2):245-51 [11142099.001]
  • [Cites] Genomics. 2004 Oct;84(4):647-60 [15475242.001]
  • [Cites] Biochem J. 1969 Nov;115(2):241-7 [5378381.001]
  • [Cites] Am J Hum Genet. 1979 Mar;31(2):125-35 [36752.001]
  • [Cites] Clin Chem. 1988 Nov;34(11):2357-9 [3141087.001]
  • [Cites] Cell Prolif. 1993 Jul;26(4):327-36 [8343561.001]
  • [Cites] Biochem Pharmacol. 1995 Oct 26;50(9):1433-43 [7503794.001]
  • [Cites] DNA Cell Biol. 1996 Mar;15(3):255-62 [8634154.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):31-8 [9097976.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1413-9 [11440994.001]
  • [Cites] Oncogene. 2002 May 30;21(24):3909-16 [12032829.001]
  • [Cites] Methods. 2002 Jun;27(2):144-9 [12095273.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):69-75 [12359353.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):453-8 [12355068.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2071-6 [9395204.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):81-90 [12538352.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12(7):791-801 [12651874.001]
  • [Cites] Biochem Soc Trans. 2003 Apr;31(2):375-80 [12653642.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3740S-3747S [14608108.001]
  • [Cites] Mutat Res. 2004 Apr 14;548(1-2):53-9 [15063136.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30 [15313459.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • (PMID = 20092614.001).
  • [ISSN] 1741-7007
  • [Journal-full-title] BMC biology
  • [ISO-abbreviation] BMC Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R21 CA131646; United States / NCI NIH HHS / CA / CA016056; United States / NCI NIH HHS / CA / R21 CA121216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6R795CQT4H / 5-Methylcytosine
  • [Other-IDs] NLM/ PMC2845099
  •  go-up   go-down


38. Goodman M, Bostick RM, Dash C, Flanders WD, Mandel JS: Hypothesis: oxidative stress score as a combined measure of pro-oxidant and antioxidant exposures. Ann Epidemiol; 2007 May;17(5):394-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We illustrate this approach by using data from two previously-conducted case-control studies: a colonoscopy-based colorectal adenoma study, and a population-based prostate cancer study.
  • In this pilot illustration we found a substantial decrease in risk associated with a high OSS for both prostate cancer and colorectal adenoma.
  • [MeSH-major] Antioxidants / administration & dosage. Colorectal Neoplasms / epidemiology. Diet. Oxidative Stress / physiology. Prostatic Neoplasms / epidemiology. Reactive Oxygen Species / adverse effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Epidemiol. 2007 Nov;17(11):930; author reply 931 [17855113.001]
  • (PMID = 17462547.001).
  • [ISSN] 1047-2797
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Reactive Oxygen Species
  • [Number-of-references] 72
  •  go-up   go-down


39. Prada Gómez PJ, de la Rua Calderón A, Romo Fonseca I, Evia Suárez M, Abascal García JM, Juan Rijo G, Fernández García J, González Sancho JM, Abascal García R, Rodríguez-Fernández R: High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience. Clin Transl Oncol; 2005 Oct;7(9):389-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience.
  • INTRODUCTION: It has been well documented that the outcome of prostate cancer treatment depends on the dose administered.
  • Between June 1998 and December 2004, 100 patients with adenoma of the prostate were treated with 46 Gy of external irradiation to the pelvis and 2 HDR brachytherapy fractions (each of 1150 cGy) at the end of weeks 1 and 3 of a 5-week radiotherapy course.
  • CONCLUSIONS: The good results of local control, disease-free survival and few complications that the external radiotherapy combined with HDR brachytherapy have shown suggest that the method should be considered as first-choice in the treatment of prostate tumours of high- and intermediate-risk.
  • [MeSH-major] Brachytherapy / methods. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Disease-Free Survival. Follow-Up Studies. Humans. Male. Postoperative Complications. Prostate / pathology. Prostate / radiation effects. Prostate / surgery. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1019-27 [7493828.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] Urol Clin North Am. 2001 Aug;28(3):555-65 [11590814.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Urology. 2003 Jul;62(1):86-91; discussion 91-2 [12837428.001]
  • [Cites] Radiother Oncol. 2000 Dec;57(3):273-8 [11104885.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1646-9 [15073852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1257-63 [7493850.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):73-81 [9212007.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):525-33 [9635698.001]
  • [Cites] Arch Esp Urol. 2005 Apr;58(3):213-26; discussion 224 [15906615.001]
  • [Cites] J Urol. 2004 Sep;172(3):910-4 [15310996.001]
  • [Cites] J Urol. 2003 Mar;169(3):974-9; discussion 979-80 [12576825.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):161-71 [7543891.001]
  • [Cites] Radiother Oncol. 1997 Sep;44(3):237-44 [9380822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81-90 [11777625.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):47-54 [8270459.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):823-32 [10705002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):359-71 [8420886.001]
  • [Cites] Arch Esp Urol. 1999 Jan-Feb;52(1):32-8; discussion 38-9 [10101885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-9 [1917622.001]
  • [Cites] Arch Esp Urol. 1998 Nov;51(9):890-6 [9887562.001]
  • [Cites] Urol Clin North Am. 1993 Nov;20(4):713-25 [7505980.001]
  • [Cites] Urology. 1989 Jul;34(1):1-9 [2749951.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23 ):3904-11 [11099319.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):875-9 [8751395.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):295-300 [9233866.001]
  • (PMID = 16238973.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


40. Pinsky PF, Schoen RE, Weissfeld JL, Church T, Yokochi LA, Doria-Rose VP, Prorok P: The yield of surveillance colonoscopy by adenoma history and time to examination. Clin Gastroenterol Hepatol; 2009 Jan;7(1):86-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The yield of surveillance colonoscopy by adenoma history and time to examination.
  • BACKGROUND & AIMS: Surveillance colonoscopy is recommended for subjects with a history of adenomas but there is limited information on the yield of surveillance.
  • METHODS: A sample of subjects in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial with abnormal flexible sigmoidoscopy and follow-up colonoscopy were queried about subsequent surveillance colonoscopy over a 10-year period.
  • Subjects with advanced adenomas, nonadvanced adenoma, nonadenomatous polyps, and no polyps at baseline were included.
  • RESULTS: At the first surveillance, 10.5% had advanced adenoma and 37% had any adenoma in the advanced adenoma group (n = 1057), compared with rates of 6.8% and 32% (nonadvanced adenoma: n = 765), 4.9% and 22% (nonadenomatous polyps: n = 658), and 3.1% and 16% (no polyps: n = 127) (P < .0001, linear trend test).
  • Mean (SD) time intervals (years) from baseline colonoscopy to first surveillance were 3.4 (2.0) for advanced adenoma, 4.3 (2.0) for nonadvanced adenoma, 4.5 (2.0) for nonadenomatous polyps, and 4.7 (2.0) for no polyps.
  • There were no increasing (or decreasing) trends in the observed rate of advanced adenoma or any adenoma with time to the initial surveillance examination in any baseline group.
  • Among subjects with a second surveillance examination, adenoma findings at both baseline and first surveillance influenced the rates of advanced adenoma and any adenoma at second surveillance.
  • CONCLUSIONS: Subjects with baseline advanced adenomas are more likely to have recurrent advanced adenomas at initial surveillance.
  • The lack of association between recurrence rates and time to surveillance suggests limitations in our understanding of the biology of adenoma development.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonoscopy. Mass Screening / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829395.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


41. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Reding DJ, Hayes RB, Church T, Yurgalevich S, Doria-Rose VP, Hickey T, Riley T, Berg CD: Utilization of surveillance colonoscopy in community practice. Gastroenterology; 2010 Jan;138(1):73-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: The recommended timing of surveillance colonoscopy for individuals with adenomatous polyps is based on adenoma histology, size, and number.
  • METHODS: We retrospectively queried participants in the Prostate, Lung, Colorectal, and Ovarian Cancer screening trial in 9 US communities about use of surveillance colonoscopy.
  • Subjects whose initial colonoscopy showed advanced adenoma (AA), nonadvanced adenoma (NAA), or no adenoma (NA) findings were included.
  • [MeSH-major] Adenoma / epidemiology. Adenomatous Polyps / epidemiology. Colonic Neoplasms / epidemiology. Colonoscopy / utilization. Community Health Services / statistics & numerical data. Gastroenterology / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):96-104 [12118964.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):129-31 [12118971.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1237-46 [12818263.001]
  • [Cites] Ann Intern Med. 2004 Aug 17;141(4):264-71 [15313742.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 1;20(5):507-15 [15339322.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 6;97(13):989-97 [15998952.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1151-62 [16230069.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] JAMA. 2006 May 24;295(20):2366-73 [16720822.001]
  • [Cites] Ann Intern Med. 2006 Nov 7;145(9):654-9 [17088578.001]
  • [Cites] Am J Epidemiol. 2007 Apr 15;165(8):874-81 [17244633.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1077-85 [17698067.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):419-26 [18347350.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jan;7(1):86-92 [18829395.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 May;7(5):562-7; quiz 497 [19138760.001]
  • [Cites] Can Fam Physician. 2001 Sep;47:1811-3, 1815 [11570307.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):619-24 [10702214.001]
  • [CommentIn] Gastroenterology. 2010 Jan;138(1):27-30 [19932659.001]
  • (PMID = 19818779.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000056-440770; United States / NCI NIH HHS / CN / N01-CN2551
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS151861; NLM/ PMC2813330
  •  go-up   go-down


42. Mariano MB, Tefilli MV, Graziottin TM, Morales CM, Goldraich IH: Laparoscopic prostatectomy for benign prostatic hyperplasia--a six-year experience. Eur Urol; 2006 Jan;49(1):127-31; discussion 131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic prostatectomy for benign prostatic hyperplasia--a six-year experience.
  • PURPOSE: The Authors present their results using laparoscopic prostatectomy in the treatment of large benign prostatic hyperplasia (BPH).
  • RESULTS: The average prostate weight was 144.50+/-41.74 gm.
  • CONCLUSIONS: The results demonstrate that resection of large prostatic adenomas can be performed with a laparoscopic approach.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery


43. Belaïdouni N, Peuchmaur M, Perret C, Florentin A, Benarous R, Besnard-Guérin C: Overexpression of human beta TrCP1 deleted of its F box induces tumorigenesis in transgenic mice. Oncogene; 2005 Mar 24;24(13):2271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent evidence implicates mutations and overexpresssion of beta TrCP1 in human prostate and colon tumors, respectively, suggesting that deregulated beta TrCP1 may be involved in tumorigenesis.
  • We found that 46% (16/35) of the transgenic mice that overexpressed the transgenes developed either intestinal adenomas (10/35) or hepatic (4/35) or urothelial (2/35) tumors.
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Animals. Cytoskeletal Proteins / genetics. Humans. Intestinal Neoplasms / genetics. Intestinal Neoplasms / pathology. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Mice. Mice, Transgenic. Sequence Deletion. Trans-Activators / genetics. beta Catenin

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735746.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / CTNNB1 protein, mouse; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin; 0 / beta-Transducin Repeat-Containing Proteins
  •  go-up   go-down


44. Glading AJ, Ginsberg MH: Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling. Dis Model Mech; 2010 Jan-Feb;3(1-2):73-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, KRIT1 regulates beta-catenin signaling, and Krit1(+/-) mice are more susceptible to beta-catenin-driven intestinal adenomas.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thromb Haemost. 2007 Jul;5 Suppl 1:32-40 [17635706.001]
  • [Cites] J Cell Biol. 2007 Oct 22;179(2):247-54 [17954608.001]
  • [Cites] Neurogenetics. 2007 Nov;8(4):249-56 [17657516.001]
  • [Cites] Mol Cancer Res. 2007 Dec;5(12):1296-303 [18171987.001]
  • [Cites] Carcinogenesis. 2008 Mar;29(3):666-72 [18204079.001]
  • [Cites] J Cell Sci. 2008 Jul 1;121(Pt 13):2224-34 [18565826.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):923-34 [18604199.001]
  • [Cites] Cardiovasc Res. 2008 Sep 1;79(4):679-88 [18490349.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2770-9 [18641366.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):6920-9 [19029934.001]
  • [Cites] Dis Model Mech. 2008 Nov-Dec;1(4-5):275-81 [19093037.001]
  • [Cites] Nat Med. 2009 Feb;15(2):169-76 [19151727.001]
  • [Cites] Nat Med. 2009 Feb;15(2):177-84 [19151728.001]
  • [Cites] Hum Mol Genet. 2009 Mar 1;18(5):919-30 [19088123.001]
  • [Cites] Dis Model Mech. 2009 Mar-Apr;2(3-4):168-77 [19259391.001]
  • [Cites] Hum Mutat. 2009 Jun;30(6):1003-11 [19370760.001]
  • [Cites] Hum Mol Genet. 1999 Nov;8(12):2325-33 [10545614.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7219-25 [10602475.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1179-91; discussion 1191-2 [10807251.001]
  • [Cites] Asian J Androl. 2000 Sep;2(3):167-71 [11225974.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1049-60 [11381089.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):188-92 [11459890.001]
  • [Cites] Biochemistry (Mosc). 2001 Oct;66(10):1174-86 [11736639.001]
  • [Cites] Acta Haematol. 2001;106(4):148-56 [11815711.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21657-65 [11940574.001]
  • [Cites] Mech Dev. 2002 Sep;117(1-2):363-7 [12204286.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6367-70 [12438216.001]
  • [Cites] Haematologica. 2003 Apr;88(4):429-37 [12681970.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8085-9 [14678957.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52587-97 [14506247.001]
  • [Cites] Development. 2004 Mar;131(6):1437-48 [14993192.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Apr;5(4):261-70 [15071551.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):365-76 [15163311.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35127-32 [15166221.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L816-23 [15220112.001]
  • [Cites] Cell. 1989 Jan 13;56(1):77-84 [2642744.001]
  • [Cites] Oncogene. 1992 Sep;7(9):1705-11 [1323817.001]
  • [Cites] Prostate. 1994 Oct;25(4):177-88 [8084835.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4 [7576992.001]
  • [Cites] Neurosurgery. 1996 May;38(5):915-24; discussion 924-5 [8727816.001]
  • [Cites] J Cell Biochem. 1996 Jun 15;61(4):514-23 [8806074.001]
  • [Cites] Nature. 1996 Oct 17;383(6601):627-30 [8857539.001]
  • [Cites] Mol Carcinog. 1996 Oct;17(2):84-91 [8890957.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2036-41 [9058725.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1A):93-8 [9066635.001]
  • [Cites] J Cell Sci. 1997 Mar;110 ( Pt 5):583-8 [9092940.001]
  • [Cites] Oncogene. 1997 Aug 28;15(9):1043-9 [9285558.001]
  • [Cites] Pancreas. 1998 May;16(4):491-8 [9598810.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45 [10085258.001]
  • [Cites] Cell. 1999 Jul 23;98(2):147-57 [10428027.001]
  • [Cites] Eur J Cell Biol. 1999 Aug;78(8):561-6 [10494862.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):189-93 [10508515.001]
  • [Cites] Semin Cell Dev Biol. 2004 Dec;15(6):657-63 [15561585.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1950-5 [15374886.001]
  • [Cites] Circ Res. 2005 Feb 18;96(3):308-18 [15662032.001]
  • [Cites] Hum Mol Genet. 2005 Sep 1;14(17):2521-31 [16037064.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 Sep;5(5):391-6 [16131422.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31906-12 [16027153.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):459-65 [16099633.001]
  • [Cites] Cell Cycle. 2005 Nov;4(11):1522-39 [16258275.001]
  • [Cites] Exp Cell Res. 2006 Feb 15;312(4):457-67 [16368435.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):5288-99 [16361708.001]
  • [Cites] Cell. 2006 Mar 10;124(5):1055-68 [16530050.001]
  • [Cites] Development. 2006 Aug;133(16):3139-46 [16873582.001]
  • [Cites] J Med Genet. 2006 Sep;43(9):716-21 [16571644.001]
  • [Cites] Dev Dyn. 2006 Nov;235(11):3110-20 [17013885.001]
  • [Cites] Nat Cell Biol. 2006 Nov;8(11):1223-34 [17060906.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1658-64 [17106247.001]
  • (PMID = 20007487.001).
  • [ISSN] 1754-8411
  • [Journal-full-title] Disease models & mechanisms
  • [ISO-abbreviation] Dis Model Mech
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL31950; United States / NIAMS NIH HHS / AR / R01 AR027214; United States / NIAMS NIH HHS / AR / AR27214; United States / NHLBI NIH HHS / HL / P01 HL031950; United States / NIAMS NIH HHS / AR / R37 AR027214; United States / NHLBI NIH HHS / HL / P01 HL078784; United States / NHLBI NIH HHS / HL / HL078784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Krit1 protein, mouse; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins; 0 / beta Catenin; EC 3.6.5.2 / rap1 GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2806902
  •  go-up   go-down


45. Trapeznikova MF, Urenkov SB, Zubrilina NM, Podoĭnitsyn AA: [Current trends in the treatment of urological patients with transplanted kidney]. Urologiia; 2009 Mar-Apr;(2):9-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the patients had urolithiasis, prostatic adenoma, some patients had renal cyst, implanted kidney tumor, tumor of the arteriosclerotic kidneys, posterior urethra stricture, posterior urethra valve.
  • Kidney recipients with prostatic adenoma (2 and 5 years after transplantation) in 3 cases were subjected to scheduled TUR because of manifest obstructive symptoms.
  • Urethral nitinol stenting was made in one patient with AUR and prostatic size over 60 cm3, TUR was made 4 months later.
  • Prostatic adenoma is treated, as a rule, surgically (TUR of the prostate).
  • [MeSH-major] Kidney Transplantation. Prostatic Hyperplasia / therapy. Urologic Diseases / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526868.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


46. Moslehi R, Chatterjee N, Church TR, Chen J, Yeager M, Weissfeld J, Hein DW, Hayes RB: Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics; 2006 Sep;7(6):819-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma.
  • BACKGROUND: Cigarette use is associated with greater risk for colorectal adenoma, a colorectal cancer precursor.
  • METHODS: In the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, we compared NAT1 and NAT2 gene variant distributions for 772 cases with left-sided advanced adenoma and 777 gender and age-matched controls.
  • RESULTS: Risks for advanced colorectal adenoma were significantly increased among recent smokers (current smokers or those who quit less than 10 years ago) (odds ratio [OR] = 2.3, 95% confidence interval [CI]: 1.7-3.1) and among those who smoked more than 20 cigarettes per day (OR = 1.7, 95% CI: 1.3-2.2), compared with nonsmokers.
  • CONCLUSIONS: Our study indicated that NAT2 gene variants associated with a slow acetylator phenotype were more susceptible to the effects of tobacco smoking with respect to adenoma risk, providing leads for disease prevention.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16981843.001).
  • [ISSN] 1462-2416
  • [Journal-full-title] Pharmacogenomics
  • [ISO-abbreviation] Pharmacogenomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-34627; United States / NCI NIH HHS / CA / CA034627-21; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA034627; United States / NCI NIH HHS / CA / R01 CA034627-21
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


47. Klausner AP, Anderson BB, Espy PG, Despradel VM, Grob BM: Long term prostate-specific antigen trends following subcapsular prostatectomy. Can J Urol; 2010 Dec;17(6):5442-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term prostate-specific antigen trends following subcapsular prostatectomy.
  • INTRODUCTION: The purpose of this study was to evaluate the utility of prostate-specific antigen (PSA) screening for prostate cancer after subcapsular prostatectomy.
  • Patients were categorized into benign and malignant groups based on a diagnosis of prostate cancer identified in the surgical specimen or during subsequent follow up.
  • Collected data included patient age, preoperative and postoperative PSA values, prostate volume determined by surgical specimen weight, and pathologic diagnosis.
  • Preoperative and postoperative PSA velocities were calculated for patients with adequate data and average values were compared to determine factors that were predictive of a confirmed prostate cancer diagnosis.
  • Six (19%) were ultimately diagnosed with prostate cancer and 25 (81%) were never diagnosed with prostate cancer.
  • Postoperative PSA velocity was found to be significantly higher for patients in the malignant group (1.22 ± 1.32 ng/mL/yr) as compared to patients in the benign group (0.06 ± 0.15 ng/mL/yr) (p = 0.003).
  • CONCLUSIONS: After subcapsular prostatectomy, patients with prostate cancer in the surgical specimen or who developed prostate cancer during long term follow up had elevated PSA velocity compared to patients who had no evidence of cancer in the surgical specimen or in follow up.
  • [MeSH-major] Adenoma / blood. Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Hyperplasia / blood. Prostatic Neoplasms / blood


48. Folarin AA, Konerding MA, Timonen J, Nagl S, Pedley RB: Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography. Microvasc Res; 2010 Jul;80(1):89-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this study we investigated the three-dimensional properties of colonic tumour vasculature in both human clinical tissues (normal mucosa control [n=20], carcinoma [n=20] and adenoma [n=6]) and murine colorectal xenografts (LS147T [n=6] and SW1222 [n=6]).

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20303995.001).
  • [ISSN] 1095-9319
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL094567; United Kingdom / Cancer Research UK / / C34/A5149; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS391359; NLM/ PMC4398341
  •  go-up   go-down


49. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA: Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int; 2006 Jun;97(6):1229-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
  • The authors used preoperative PSA level as a marker of prostate volume and assessed its potential predictive value on the level of clinical efficacy for treating symptomatic BPH.
  • OBJECTIVE: To report the 3-year results and analyse whether total prostate-specific antigen (tPSA) levels and prostate volume before treatment can predict the level of clinical efficacy of photoselective vaporization prostatectomy (PVP) for treating obstructive benign prostatic disease, as high-power potassium-titanyl-phosphate (KTP) laser prostatectomy was previously shown to be safe and to efficiently vaporize prostatic adenoma secondary to benign prostatic hyperplasia (BPH), with minimal bleeding and morbidity.
  • A subanalysis evaluating each patient for tPSA and prostate volume before PVP was conducted, with a long-term assessment of the primary efficacy outcomes at 3 years after PVP.
  • Each subgroup was assessed for changes from baseline in American Urological Symptom Index (AUA SI) score, quality of life (QoL) score, peak urinary flow rate (Q(max)), prostate volume, and postvoid residual urine volume (PVR) at 1, 2 and 3 years after PVP.
  • The mean (sd) prostate volume for group 1 was 48.3 (16.7) mL (87 men), and was 83.1 (30.6) mL (52 men) in group 2.
  • However, the overall results achieved with PVP were very positive and durable to 3 years, irrespective of tPSA level and prostate volume.
  • [MeSH-major] Laser Therapy / methods. Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Urologic Diseases / surgery


50. Robles M, Sarmiento MA, Rojas A, Villarejo MA: [Bladder rupture during transurethral prostate resection]. Rev Esp Anestesiol Reanim; 2010 Feb;57(2):131
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder rupture during transurethral prostate resection].
  • [Transliterated title] Rotura vesical durante resección transuretral de próstata.
  • [MeSH-major] Intraoperative Complications / etiology. Solutions / adverse effects. Transurethral Resection of Prostate. Urinary Bladder / injuries
  • [MeSH-minor] Adenoma / surgery. Administration, Intravesical. Aged. Extravasation of Diagnostic and Therapeutic Materials / etiology. Humans. Male. Pressure / adverse effects. Prostatic Neoplasms / surgery. Rupture / etiology. Therapeutic Irrigation / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337012.001).
  • [ISSN] 0034-9356
  • [Journal-full-title] Revista española de anestesiología y reanimación
  • [ISO-abbreviation] Rev Esp Anestesiol Reanim
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Solutions
  •  go-up   go-down


51. Purdue MP, Mink PJ, Hartge P, Huang WY, Buys S, Hayes RB: Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States). Cancer Causes Control; 2005 Oct;16(8):965-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States).
  • OBJECTIVE: Findings from some epidemiologic studies of colorectal cancer and adenoma suggest that the protective effect of post-menopausal hormone replacement therapy (HRT) may differ across categories of age and body mass index (BMI).
  • We conducted an analysis of women participating in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to investigate the relationship between HRT use and prevalent adenoma, both overall and across different population subgroups.
  • We identified 1468 women with at least one left-sided adenoma and 19,203 without adenoma or colorectal cancer.
  • RESULTS: Compared to never use of HRT, current use was associated with a decreased prevalence of left-sided adenoma (odds ratio (OR) 0.85; 95% confidence interval (CI) 0.75-0.97).
  • Other reproductive factors were not significantly associated with adenoma prevalence.
  • CONCLUSIONS: Our findings suggest that current HRT use may protect against colorectal adenoma, and that this protective effect is short-lived following cessation of use.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / epidemiology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology. Hormone Replacement Therapy / utilization. Mass Screening / statistics & numerical data


52. Kogan MI, Kireev AIu: [The questionnaire of integral assessment of male sexuality]. Urologiia; 2009 Jan-Feb;(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proposed questionnaire can serve as a tool for studies of male sexuality in relation with different pathological processes: prostatic adenoma and cancer, metabolic syndrome, erectile dysfunction and others.

  • MedlinePlus Health Information. consumer health - Sexual Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432233.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


53. Cohen RJ, Shannon BA: Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma. Pathology; 2007 Oct;39(5):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Diverticulum / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886106.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


54. Seki N, Kai N, Seguchi H, Takei M, Yamaguchi A, Naito S: Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology; 2006 Feb;67(2):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity.
  • OBJECTIVES: To elucidate the predictive factors regarding the treatment outcomes after transurethral resection of the prostate for symptomatic benign prostatic enlargement with detrusor underactivity.
  • METHODS: A retrospective study was conducted in 190 patients with detrusor underactivity of 1397 men who had undergone transurethral resection of the prostate.
  • All patients had completed the International Prostate Symptom Score and quality-of-life (QOL) questionnaires and had undergone a full urodynamic analysis before surgery.
  • The outcomes were assessed at 3 and 12 months postoperatively using the International Prostate Symptom Score, QOL score, and peak urinary flow rate.
  • CONCLUSIONS: In selected patients with benign prostatic enlargement associated with detrusor underactivity, greater baseline storage symptom scores and the presence of DO were negative predictive factors for QOL improvement.
  • Baseline DO was also predictive of poorer improvement in the subjective symptoms after transurethral resection of the prostate.
  • [MeSH-major] Prostatic Hyperplasia / complications. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Bladder Neck Obstruction / complications

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16461081.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Blah M, Nouira Y, Kallel Y, Hafsia GH, Horchani A: [Bladder herniation]. Ann Chir; 2005 Dec;130(10):633-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis is frequently done during surgery.
  • Retrograde urethrocystography or computerized tomography confirm the diagnosis.
  • We report a case of bilateral inguinal hernia involving the bladder at the right side in a 87 years old man who had a surgical history of transvesical adenomectomy of the prostate.
  • The diagnosis was done on the retrograde urethrocystography.
  • [MeSH-minor] Adenoma / surgery. Aged. Functional Laterality. Humans. Male. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043116.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


56. Fernando MA, Heaney AP: Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol; 2005 Dec;19(12):3085-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas.
  • Doxazosin (dox), a selective alpha(1)-adrenergic receptor antagonist, used to treat hypertension, also inhibits prostate cancer cell proliferation.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / drug therapy. Adenoma / drug therapy. Adrenergic alpha-1 Receptor Antagonists. Adrenergic alpha-Antagonists / therapeutic use. Antineoplastic Agents / therapeutic use. Doxazosin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020484.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Receptors, Adrenergic, alpha-1; 0 / Tumor Necrosis Factor-alpha; 139874-52-5 / NF-kappaB inhibitor alpha; 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; NW1291F1W8 / Doxazosin
  •  go-up   go-down


57. Lee YH, Chiu AW, Huang JK: Comprehensive study of bladder neck contracture after transurethral resection of prostate. Urology; 2005 Mar;65(3):498-503; discussion 503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive study of bladder neck contracture after transurethral resection of prostate.
  • OBJECTIVES: To test the validity of transurethral resection of the prostate (TURP) plus transurethral incision (TUI) of bladder neck as an alternative to TUI of the prostate, a nonrandomized and retrospective study was done to review comprehensively the incidence of, severity of, and risk factors for bladder neck contracture (BNC) in patients with benign prostatic hyperplasia who underwent transurethral surgery.
  • METHODS: The evaluation parameters included age, prostate-specific antigen level, urinalysis and uroflowmetry findings, voided volume, presence of vesical stones and urinary retention, surgical type, adenoma weight, and perioperative morbidities.
  • The adenoma weight, blood transfusion, and postoperative maximal and mean flow rate in patients with BNC were significantly less than in patients without BNC.
  • BNC was completely prevented using TURP plus TUI if the adenoma weight was greater than 30 g.
  • However, in the TURP group, 4% of patients developed BNC even with an adenoma weight greater than 50 g.
  • Multivariate analyses showed that adenoma weight and surgical type were significant risk factors for BNC.
  • CONCLUSIONS: TURP plus TUI provides a pathologic diagnosis, and with minimal morbidity, it can be an alternative to TUI of the prostate in selected patients.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / adverse effects. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780363.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • The study was made of possibilities of methyl-specific PCR-test of glutathione-S-transferase P1 (GSTP1) gene in differential diagnosis of prostatic cancer: sensitivity of the test, comparison of reagents of Russian and foreign production.
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • The results show that the above test with domestic reagents is rather perspective for differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] DNA / blood. DNA / metabolism. DNA / urine. DNA Methylation. Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


59. Bogdanov AB, Luk'ianov IV, Veliev EI: [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma].
  • Clinical effects and safety of doxazosine + finasteride combination were studied in patients with obstructive and irritative symptoms due to prostatic adenoma (PA).
  • Lower urinary tract symptoms according to IPSS, size of the prostatic gland, Qmax and Qmid, bladder capacity, residual urine volume, blood pressure, PSA level, sexual function, side effects were assessed before and after combined use of the drugs in 30 patients aged 58 to 83 years (mean age 70.5 years).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248599.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


60. Chepurov AK, Bulantsev DIu: [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma]. Urologiia; 2007 Jan-Feb;(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urethra / pathology. Urethra / physiopathology. Urinary Bladder / pathology. Urinary Bladder / physiopathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472005.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 71
  •  go-up   go-down


61. Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr: Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol; 2007 Nov-Dec;25(6):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy.
  • OBJECTIVES: Prostate capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
  • Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and prostate cancer in a series of patients undergoing radical cystoprostatectomy.
  • METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the prostate peripheral zone/capsule from the prostate adenoma and bladder after surgery.
  • These specimens were evaluated for bladder and prostate cancer grade, stage, and largest diameter of prostate cancer.
  • Clinical variables were compared between patients with and without carcinoma involving the prostate using standard statistical software.
  • RESULTS: Of patients, 57% had cancer involving the prostate at radical cystoprostatectomy.
  • There were 9 patients (26%) who had urothelial carcinoma involving the prostate; only prostatic urethral biopsy identified these patients before radical cystoprostatectomy.
  • Prostate adenocarcinoma was evident in 16 of 35 (47%) patients, with a majority involving the prostate peripheral zone/capsule (43%).
  • There were 4 patients (11%) who had clinically significant prostate cancer (Gleason sum >6 or tumor volume >0.5 cm(3)).
  • Patients with prostate cancer were significantly older than patients without prostate cancer (P = 0.01).
  • CONCLUSIONS: No clinical variable can confidently predict patients with prostate cancer involving the prostate.
  • Because a majority of patients undergoing radical cystoprostatectomy have cancer involving their prostate, preoperative evaluation with prostatic urethral and prostate biopsy may be useful to guide patient selection for prostate capsule sparing cystectomy.
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047952.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Desai MM, Fareed K, Berger AK, Astigueta JC, Irwin BH, Aron M, Ulchaker J, Sotelo R: Single-port transvesical enucleation of the prostate: a clinical report of 34 cases. BJU Int; 2010 May;105(9):1296-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-port transvesical enucleation of the prostate: a clinical report of 34 cases.
  • OBJECTIVE: To present our experience with single-port transvesical enucleation of the prostate (STEP) in 34 patients with large-volume benign prostatic hyperplasia (BPH).
  • The mean prostate volume estimated by transrectal ultrasonography was 102.5 mL and the mean baseline prostate-specific antigen level was 6.7 ng/mL.
  • After establishing pneumovesicum, the prostate adenoma was enucleated transvesically using standard laparoscopic instruments, and the adenoma was extracted in pieces through the port.
  • Digital assistance expedited enucleation of the apical adenoma in 19 (55%) cases.
  • Under pneumovesicum using laparoscopic visualization, the entire adenoma can be effectively enucleated and expeditiously extracted through the novel single port.
  • [MeSH-major] Laparoscopy. Laser Therapy / methods. Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346053.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Berndt SI, Huang WY, Chatterjee N, Yeager M, Welch R, Chanock SJ, Weissfeld JL, Schoen RE, Hayes RB: Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma. Carcinogenesis; 2007 Sep;28(9):1965-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma.
  • To investigate the association between genetic variants in TGFB1 and the risk of colorectal adenoma, we conducted a case-control study of 754 advanced adenoma cases and 769 controls from the baseline screening exam of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
  • Cases included participants diagnosed with advanced left-sided adenoma (>or=1 cm, high-grade dysplasia or villous characteristics), and controls were subjects without evidence of a left-sided polyp by sigmoidoscopy.
  • Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for the association between each polymorphism and adenoma.
  • The high TGFB1 producer genotypes, -509TT and 10Pro/Pro, were associated with an increased risk of colorectal adenoma compared with other genotypes (OR = 1.51, 95% CI: 1.04-2.20 and OR = 1.37, 95% CI: 1.02-1.86, respectively).
  • These increased risks, particularly for -509TT, were greater for persons with multiple adenomas (OR = 1.89, 95% CI: 1.16-3.09, P = 0.01) and individuals with rectal adenoma (OR = 2.95, 95% CI: 1.66-5.26, P = 0.0002).
  • In conclusion, variants that enhance TGFB1 production may be associated with an increased risk of advanced colorectal adenoma.
  • [MeSH-minor] Adenoma / genetics. Aged. Female. Gene Expression Regulation, Neoplastic. Genetic Variation. Genotype. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Reference Values. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615257.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


64. Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G: S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg Pathol; 2009 Jul;33(7):1031-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
  • Nephrogenic adenoma is a benign lesion that may occur at any site of the genitourinary tract, usually in association with previous urothelial injuries.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic adenocarcinoma, particularly with lesions arising in the prostatic urethra.
  • Alpha-methylacyl-CoA racemase (AMACR), a recently identified prostate cancer marker, has also been found to be expressed in renal tubules and in some renal epithelial neoplasms.
  • In this study, we investigated the expression of S100A1 and AMACR in 18 nephrogenic adenomas and in 100 prostatic adenocarcinomas.
  • A strong and distinct cytoplasmic or nucleocytoplasmic staining of S100A1 was found in 17 out of 18 cases of nephrogenic adenoma (94%), but never in prostatic adenocarcinoma.
  • In contrast, AMACR expression was detected in 14 of 18 nephrogenic adenomas (78%) and in 96 of 100 prostatic adenocarcinomas (96%).
  • We conclude that (1) S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from prostatic adenocarcinoma;.
  • (3) given that both S100A1 and AMACR have been reported to be expressed in renal tubular cells and in a subset of renal cell neoplasms, our findings confirm the histogenetic relationship between nephrogenic adenoma and renal tubular epithelium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Prostatic Neoplasms / diagnosis. S100 Proteins / biosynthesis. Urogenital Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Racemases and Epimerases / biosynthesis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384190.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / S100A1 protein; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


65. Neĭmark AI, Snegirev IV, Neĭmark BA: [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma]. Urologiia; 2006 Mar-Apr;(2):75, 77-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma].
  • The authors analyse preoperative preparation of 91 patients with benign prostatic hyperplasia (BPH).
  • Two groups of patients received conventional preparation (group 1) and magnetotherapy (group 2) before TUR of the prostate.
  • The examination covered immune system, bacteriological indices of urine and prostatic tissue.
  • Conventional preoperative preparation fails to correct immunity, to change bacterial urine flora, to improve hemodynamics in the prostate.
  • [MeSH-major] Ferrosoferric Oxide / therapeutic use. Physical Therapy Modalities / instrumentation. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Tract Infections / prevention & control
  • [MeSH-minor] B-Lymphocytes / immunology. Humans. Leukocyte Count. Male. Perioperative Care / methods. Prostate / microbiology. Rectum. T-Lymphocytes / immunology. Urine / microbiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708596.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


66. Sung W, Park BD, Lee S, Chang SG: Villous adenoma of the urinary bladder. Int J Urol; 2008 Jun;15(6):551-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villous adenoma of the urinary bladder.
  • Villous adenomas arising in the urinary tract are an uncommon occurrence.
  • They have been identified in the urachus, urethra, prostate, and throughout the bladder.
  • Villous adenomas arising in the bladder are rare tumors that have been described as isolated cases and a few case series.
  • We report a new case of a large villous adenoma arising in the bladder that was treated by transurethral resection.
  • [MeSH-major] Adenoma, Villous / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489648.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


67. Verger-Kuhnke AB, Reuter MA, Epple W, Ungemach G, Beccaría ML: [Photoselective vaporization with the 80-watt KTP-laser (kalium-titanyl-phosphate) and low-hydraulic-pressure TURP in the treatment of BPH: our experience with 230 cases]. Arch Esp Urol; 2007 Mar;60(2):167-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La vaporizacion fotoselectiva de la HPB con el KTP-laser (kalium- titanyl-phosphat) de 80 watt y la RTU-P de baja presion hidraulica, experiencia en 230 casos.
  • The additional Resection was carried out in those patients with great adenomas or having a big middle lobe.
  • The group 1 (n: 50) just by laser treatment and small adenomas, the haemoglobin was reduced a 3.2% and nobody required a transfusion.
  • Group 2 (n: 180) with combined treatment of KTP-laser and TUR-P in great adenomas, the haemoglobin was reduced in average 13.7% after the intervention; 2 patients (1.1%) needed a transfusion.
  • CONCLUSION: Our study shows the advantages of combining both, the advantages to combine both surgical procedures to mainly obtain a better result in the ablation of the prostate adenoma in prostates of great size.
  • [MeSH-major] Laser Therapy / instrumentation. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484484.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Phosphates; 12690-20-9 / potassium titanylphosphate; D1JT611TNE / Titanium
  •  go-up   go-down


68. Filiadis I, Adamopoulos V, Konstandinidis E: Modification of retropubic adenomectomy: improved hemostasis and outcome. Int Urol Nephrol; 2007;39(1):169-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Our modification is based on the employment of the ligation of both the deep dorsal penile vein (DDPV) and the lateral vesicoprostatic pedicles before enucleation of adenoma in retropubic adenomectomy, for treatment of bladder outflow obstruction due to large benign prostate hyperplasia (BPH).
  • PATIENTS AND METHODS: From January 2004 till May 2005, 18 patients suffering from large BPH obstruction (mean value of adenoma 145.4 cm(3)) were operated with this modification.
  • [MeSH-minor] Blood Loss, Surgical. Hematocrit. Humans. Male. Organ Size. Prostate / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Jun;143(6):1203-4 [2342182.001]
  • [Cites] Andrologia. 1999;31 Suppl 1:77-82 [10643523.001]
  • [Cites] NCI Monogr. 1988;(7):133-7 [3173499.001]
  • [Cites] Urology. 1998 Jan;51(1):67-72 [9457291.001]
  • [Cites] Lancet. 1945 Dec 1;2(6380):693-6 [21007347.001]
  • (PMID = 17268903.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


69. Guerra Y, Lacuesta E, Marquez F, Raksin PB, Utset M, Fogelfeld L: Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary; 2010;13(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
  • We report the case of a 60 year old male who complained of headache and blurry vision--that progressed to left ophthalmoplegia and ptosis--after receiving a dose of leuprolide for Prostate cancer therapy.
  • A literature review revealed nine previously reported cases of pituitary apoplexy after GnRH agonist therapy for prostate cancer.
  • [MeSH-major] Adenoma / complications. Leuprolide / adverse effects. Pituitary Neoplasms / complications. Stroke / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Humans. Male. Middle Aged. Prostatic Neoplasms / complications. Prostatic Neoplasms / drug therapy. Sella Turcica


70. Ciccarelli A, Guerra E, De Rosa M, Milone F, Zarrilli S, Lombardi G, Colao A: PRL secreting adenomas in male patients. Pituitary; 2005;8(1):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PRL secreting adenomas in male patients.
  • Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma.
  • [MeSH-minor] Age Factors. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. Humans. Libido. Male. Prevalence. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / physiopathology. Semen / physiology. Sex Factors. Spermatogenesis. Testis / physiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Oct 31;352(9138):1455-61 [9808008.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2102-7 [9215279.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1704-11 [15070934.001]
  • [Cites] Biol Reprod. 1995 Jun;52(6):1284-90 [7632836.001]
  • [Cites] Prostate. 1994;24(3):162-6 [8115281.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):621-5 [14764772.001]
  • [Cites] Eur J Endocrinol. 2003 Mar;148(3):325-31 [12611613.001]
  • [Cites] J Androl. 1991 May-Jun;12(3):185-90 [1917682.001]
  • [Cites] Invest Urol. 1976 Jul;14(1):20-2 [955845.001]
  • [Cites] Eur J Endocrinol. 1998 Mar;138(3):286-93 [9539303.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Urol. 1989 Oct;142(4):992-4 [2795758.001]
  • [Cites] Mayo Clin Proc. 1998 Nov;73(11):1046-52 [9818037.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2338-43 [8964874.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2770-5 [15181056.001]
  • [Cites] Eur J Endocrinol. 1996 Nov;135(5):548-52 [8980156.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22 [10404830.001]
  • (PMID = 16411067.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  • [Number-of-references] 20
  •  go-up   go-down


71. Yuh B, Laungani R, Perlmutter A, Eun D, Peabody JO, Mohler JL, Stricker H, Guru KA: Robot-assisted Millin's retropubic prostatectomy: case series. Can J Urol; 2008 Jun;15(3):4101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION/OBJECTIVE: Simple prostatectomy continues to be an effective surgical option for patients with symptomatic high volume benign prostatic hyperplasia.
  • Recent trends towards minimally invasive urologic surgery, in particular for prostate cancer, have created surgical alternatives with additional potential benefits.
  • Average preoperative transrectal ultrasound estimated prostate volume exceeded 300 cm3.
  • RESULTS: Average age for the patient group was 76.7 years with mean prostate specific antigen (PSA) of 25.1.
  • The patient with the largest prostate required incision extension for removal of specimen.
  • Average adenoma weight was 301 grams (66-640).
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Prostatic Hyperplasia

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570717.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


72. Tzelepi V, Grivas P, Kefalopoulou Z, Kalofonos H, Varakis JN, Melachrinou M, Sotiropoulou-Bonikou G: Estrogen signaling in colorectal carcinoma microenvironment: expression of ERbeta1, AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression. Virchows Arch; 2009 Apr;454(4):389-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of ERalpha, ERbeta1, and the ER coregulators, amplified in breast cancer-1 (AIB-1) and transcriptional intermediary factor 2 (TIF-2), was evaluated in myofibroblasts of 107 colorectal carcinomas, 77 paired samples of normal mucosa, and 29 adenomas by immunohistochemistry.
  • Double immunostaining with a-SMA was used to identify the myofibroblasts of normal tissue, adenomas, and cancer microenvironment.
  • Nuclear expression of ERbeta1, AIB-1, and TIF-2 in myofibroblasts gradually increased from normal mucosa, through adenomas, to carcinomas.
  • Cytoplasmic ERbeta1 and TIF-2 expression was enhanced in carcinomas compared to normal mucosa and adenomas.
  • [MeSH-minor] Adenoma / metabolism. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic / metabolism. Disease Progression. Female. Fibroblasts / metabolism. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Myocytes, Smooth Muscle / metabolism. Neoplasm Staging. Nuclear Receptor Coactivator 3. Signal Transduction / physiology. Up-Regulation

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2002 Dec 27;111(7):931-41 [12507421.001]
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 1):C1-9 [10409103.001]
  • [Cites] World J Gastroenterol. 2004 Jan 15;10(2):214-7 [14716825.001]
  • [Cites] Angiogenesis. 1998;2(2):167-82 [14517472.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5331-5 [11454669.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):76-84 [16215757.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1251-8 [12763213.001]
  • [Cites] J Mol Endocrinol. 2003 Feb;30(1):13-29 [12580758.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):27-34 [18282701.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1625-33 [18285421.001]
  • [Cites] J Clin Pathol. 2000 Aug;53(8):626-9 [11002768.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):803-9 [14533013.001]
  • [Cites] Mol Endocrinol. 2003 May;17(5):792-803 [12586845.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):307-14 [16677694.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1598-605 [15735050.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3183-90 [10866309.001]
  • [Cites] Histopathology. 2007 Jun;50(7):875-80 [17543077.001]
  • [Cites] Acta Pharmacol Sin. 2006 Apr;27(4):387-94 [16539836.001]
  • [Cites] FASEB J. 2004 Jun;18(9):1016-8 [15059978.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3570-5 [10999746.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4315-9 [11389051.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):17-21 [15944762.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):146-58 [9134238.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1487-94 [15949936.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2062-71 [17332335.001]
  • [Cites] J Am Soc Nephrol. 2001 Feb;12(2):241-51 [11158214.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):329-37 [18172327.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6089-97 [11507058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6535-40 [9177253.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):632-40 [11212261.001]
  • [Cites] Curr Opin Cell Biol. 2008 Jun;20(3):310-5 [18499426.001]
  • [Cites] Mol Endocrinol. 2001 May;15(5):783-96 [11328858.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jul;126(7):829-36 [12088453.001]
  • [Cites] Prostate. 2006 Jan 1;66(1):105-14 [16114065.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1997 Oct;2(4):393-402 [10935027.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4287-92 [16309230.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(17):6571-83 [16914740.001]
  • [Cites] Stem Cell Rev. 2006;2(3):203-12 [17625256.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):207-11 [12469170.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):245-8 [10667568.001]
  • [Cites] Mol Endocrinol. 2005 Apr;19(4):833-42 [15695368.001]
  • [Cites] Endocr J. 2009;56(1):1-7 [18497452.001]
  • [Cites] Endocrinology. 2002 Sep;143(9):3427-34 [12193555.001]
  • [Cites] Mol Cell. 2007 Sep 7;27(5):691-700 [17803935.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):17-23 [15652746.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7460-8 [15615701.001]
  • [Cites] Vitam Horm. 2005;70:169-98 [15727805.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Apr;50(1):3-22 [15094156.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2960-6 [12050280.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4516-21 [8813150.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] J Pathol. 2005 Sep;207(1):53-60 [15954165.001]
  • [Cites] Steroids. 2007 Feb;72(2):135-43 [17276470.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1706-15 [15917309.001]
  • (PMID = 19277704.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / NCOA2 protein, human; 0 / Nuclear Receptor Coactivator 2; 0 / Trans-Activators; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NCOA3 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


73. Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ: The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU Int; 2005 Nov;96(7):1045-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
  • OBJECTIVES: To compare the clinical profile (age, comorbidities, symptom severity, and incidence of acute urinary retention, AUR), the type and duration of medical treatment, and indications for surgery of patients undergoing surgery for benign prostatic hyperplasia (BPH) in 1992 and 2002 at one centre.
  • The preoperative clinical profile was determined by assessing age, main comorbidities, prostatic volume, maximum urinary flow rate and symptom severity.
  • Open surgery was indicated in 18.8% of patients in 1992 (mean adenoma weight 73.8 g, sd 37.12) and in 28.6% in 2002 (79.8 g, sd 35.41; P = 0.625).
  • Significantly more patients had open surgery, perhaps because the progressive increase in prostate volume was not affected by the medical therapy used predominantly during this decade.
  • [MeSH-major] Adenoma / surgery. Patient Selection. Prostatectomy / trends. Prostatic Hyperplasia / surgery
  • [MeSH-minor] 5-alpha Reductase Inhibitors. Adrenergic alpha-Antagonists / therapeutic use. Age Factors. Aged. Chi-Square Distribution. Cross-Sectional Studies. Disease Progression. Enzyme Inhibitors / therapeutic use. Finasteride / therapeutic use. Humans. Male. Middle Aged. Phytotherapy / utilization. Prostate / surgery. Retrospective Studies

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225526.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  •  go-up   go-down


74. Halsey MA, Calder KB, Mathew R, Schlauder S, Morgan MB: Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms. J Cutan Pathol; 2010 Apr;37(4):446-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AMACR has been established as a valuable diagnostic marker for prostate cancer and has recently been shown to be useful in the diagnosis of colorectal carcinoma.
  • METHODS: Five samples of normal sebaceous glands as well as five cases each of sebaceous hyperplasia (SH), sebaceous adenoma (SA), basal cell carcinoma (BCC) with sebaceous differentiation and extraocular sebaceous carcinoma (SC) were evaluated for immunohistochemical (IHC) expression of AMACR.
  • CONCLUSIONS: The expression of AMACR is increased in benign sebaceous glands and SH; with decreasing AMACR expression in tumors with less sebaceous differentiation (i.e.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Racemases and Epimerases / metabolism. Sebaceous Gland Neoplasms / enzymology. Sebaceous Glands / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638170.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


75. Manzarbeitia F, Vela Navarrete R, Fernández-Aceñero MJ: [Early histopathological aspects of benign prostatic hyperplasia: myxoid-inflammatory nodules]. Actas Urol Esp; 2010 Jun;34(6):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early histopathological aspects of benign prostatic hyperplasia: myxoid-inflammatory nodules].
  • [Transliterated title] Aspectos histopatológicos iniciales de la hiperplasia benigna de próstata: nódulos mixo-inflamatorios.
  • OBJECTIVES: Infiltration of benign prostatic hyperplasia (BPH), nodular prostatic hyperplasia (NPH) or prostatic adenoma by mononuclear cells, predominantly lymphocytes, is a common finding in surgical specimens.
  • [MeSH-major] Prostatic Hyperplasia / pathology

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510119.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


76. Tzelepi V, Grivas P, Kefalopoulou Z, Kalofonos H, Varakis JN, Sotiropoulou-Bonikou G: Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with better [corrected] prognosis. Virchows Arch; 2009 Jan;454(1):41-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal mucosa and adenomas were also evaluated in 77 and 29 cases, respectively.
  • Statistical analysis revealed an increase in PELP1 expression in myofibroblasts from normal mucosa through adenomas to carcinomas.
  • Additionally, NCoR was expressed in the cytoplasm of cancer-associated myofibroblasts, but was rarely noted in myofibroblasts of normal mucosa or adenomas.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Co-Repressor Proteins. Cytoplasm / metabolism. Disease Progression. Female. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Middle Aged. Multivariate Analysis. Nuclear Receptor Co-Repressor 1. Prognosis. Survival Analysis. Transcription Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Virchows Arch. 2009 Feb;454(2):239
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 1):C1-9 [10409103.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1295-303 [11884528.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1904-13 [17194752.001]
  • [Cites] PLoS Biol. 2004 Feb;2(2):E7 [14737219.001]
  • [Cites] Gastroenterology. 2008 Mar;134(3):849-64 [18325394.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):321-44 [10368774.001]
  • [Cites] Nucl Recept. 2003 Jun 28;1(1):4 [12904255.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5505-12 [17545633.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13153-7 [16141343.001]
  • [Cites] Cell Cycle. 2007 Feb 15;6(4):467-70 [17312396.001]
  • [Cites] J Clin Pathol. 2000 Aug;53(8):626-9 [11002768.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1096-108 [14963108.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Mol Cell. 2004 Sep 24;15(6):937-49 [15383283.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):517-36 [14713265.001]
  • [Cites] J Mol Endocrinol. 2003 Dec;31(3):349-57 [14664699.001]
  • [Cites] PLoS Biol. 2005 Jun;3(6):e187 [15869330.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1749-50 [16990541.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):9-13 [18172289.001]
  • [Cites] Histol Histopathol. 2007 Jan;22(1):91-6 [17128415.001]
  • [Cites] FASEB J. 2004 Jun;18(9):1016-8 [15059978.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):629-36 [10225455.001]
  • [Cites] Nat Rev Genet. 2007 Apr;8(4):263-71 [17363975.001]
  • [Cites] Science. 2003 Oct 17;302(5644):393; author reply 393 [14563990.001]
  • [Cites] Nature. 2002 Oct 31;419(6910):934-9 [12410313.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):146-58 [9134238.001]
  • [Cites] Cell. 2000 Sep 15;102(6):753-63 [11030619.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1487-94 [15949936.001]
  • [Cites] Cell. 2002 Feb 22;108(4):465-74 [11909518.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2062-71 [17332335.001]
  • [Cites] Biol Pharm Bull. 2002 Oct;25(10 ):1298-302 [12392082.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):329-37 [18172327.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6089-97 [11507058.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):509-17 [15349825.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6535-40 [9177253.001]
  • [Cites] Cell Cycle. 2007 Jul 15;6(14):1748-52 [17630505.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6416-23 [15374949.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54676-86 [15491994.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1033-8 [16189147.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jul;126(7):829-36 [12088453.001]
  • [Cites] Clin Exp Metastasis. 2006;23(1):1-7 [16826428.001]
  • [Cites] Prostate. 2006 Jan 1;66(1):105-14 [16114065.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1997 Oct;2(4):393-402 [10935027.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):38272-9 [11481323.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):561-70 [16511588.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7724-32 [16140940.001]
  • [Cites] Mol Cell. 2007 Sep 7;27(5):691-700 [17803935.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):45-71 [14769827.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8 [12415108.001]
  • [Cites] Vitam Horm. 2005;70:169-98 [15727805.001]
  • [Cites] Nucl Recept Signal. 2007 May 17;5:e004 [17525794.001]
  • [Cites] Biosystems. 2006 Feb-Mar;83(2-3):81-90 [16426740.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4516-21 [8813150.001]
  • [Cites] Surgery. 2005 Aug;138(2):382-90 [16153451.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):815-8 [9486655.001]
  • (PMID = 19048289.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Co-Repressor Proteins; 0 / NCOR1 protein, human; 0 / Nuclear Proteins; 0 / Nuclear Receptor Co-Repressor 1; 0 / PELP1 protein, human; 0 / Receptors, Estrogen; 0 / Repressor Proteins; 0 / Trans-Activators; 0 / Transcription Factors
  •  go-up   go-down


77. Kolbasov DN: [Hyperbaric oxygenation in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):92-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hyperbaric oxygenation in patients with prostatic adenoma].
  • [MeSH-major] Hyperbaric Oxygenation. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526884.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 41
  •  go-up   go-down


78. Sevriukov FA, Puchkin AB, Krupin VN, Chebykin AV, Sorokin DA, Karpukhin IV, Malinina OIu, Zorin DG: [Transurethral electrosurgery of a new generation (TURis) in the treatment of the lower urinary tract and prostate diseases]. Urologiia; 2007 May-Jun;(3):28-32, 35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electrosurgery of a new generation (TURis) in the treatment of the lower urinary tract and prostate diseases].
  • Surgical interventions were made in 175 patients aged 23-87 years (mean age 64.8 years) with different diseases of the lower urinary tract (adenoma, prostatic cancer, cancer of the urinary bladder, etc.) with application of a new generation of endoscopic technique--transurethral resection in saline (TURis system) with a generator UES-40 SurgMaster (Olympus).
  • The size of the prostate in prostatic adenoma ranged from 4.8 to 121 cm3 (mean 62.5 cm3), residual urine--92.3 ml (42.6 to 310.2 ml).
  • Mean amount of the resected tissue in sclerosis of urinary bladder cervix was 7 g (5-11 g), in prostatic adenoma--41 g (10-85 g), prostatic cancer--27 g (17-49 g).
  • Incontinence was observed in 7 (5.3%) patients after removal of urethral catheter, in 5 (3.8%) patients it stopped spontaneously to the time of discharge from the hospital, 2 (1.5%) patients with prostatic cancer retained partial orthostatic incontinence.
  • Standard time limitation for transurethral resection (60-90 min) becomes insignificant in using isotonic irrigation allowing urologists to resect safely larger adenomas than it was possible earlier.
  • [MeSH-major] Electrosurgery / methods. Prostatic Diseases / surgery. Urinary Tract / surgery. Urologic Diseases / surgery. Urologic Surgical Procedures, Male / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Transurethral Resection of Prostate / instrumentation. Transurethral Resection of Prostate / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724828.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


79. Pushkar' DIu, Loran OB, Petrov SB, Kogan MI, Zhuravlev VN: [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial]. Urologiia; 2008 Jan-Feb;(1):23, 25-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial].
  • Patients with impaired micturition caused by prostatic adenoma received revocarin for 12-weeks.
  • Thus, a 12-week course of revocarin demonstrated good clinical efficacy and safety in patients with urination problems because of prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Urinary Retention / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649675.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


80. Zeng Y, Yokohira M, Takeuchi H, Saoo K, Yamakawa K, Matsuda Y, Hosokawa K, Li JQ, Ikeda M, Imaida K: Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Lett; 2005 May 26;222(2):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
  • Modifying effects of arctiin on prostate carcinogenesis in probasin/SV 40 T antigen (Tag) transgenic (TG) rats were examined.
  • Histopathological evaluation of prostate revealed that all the rats in any group developed adenocarcinoma in dorsolateral lobe of prostate, except two rats in 0.1% arctiin treated and one rat in 0.002% arctiin treated groups without prostate adenocarcinoma development.
  • However, there were no definite treatment-related changes with statistical significance in all parameters for prostate carcinomas measured in this experiment.
  • These results indicated that arctiin might not exert significant modifying effect on prostate carcinogenesis in SV 40 Tag TG rats at least under the present experiment.
  • [MeSH-major] Adenoma / physiopathology. Furans / pharmacology. Glucosides / pharmacology. Prostatic Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863263.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgen-Binding Protein; 0 / Antigens, Polyomavirus Transforming; 0 / Drugs, Chinese Herbal; 0 / Furans; 0 / Glucosides; 0 / probasin; TM5RQ949K7 / arctiin
  •  go-up   go-down


81. Iwamoto K, Hiraoka Y, Shimizu Y: Transurethral detachment prostatectomy using a tissue morcellator for large benign prostatic hyperplasia. J Nippon Med Sch; 2008 Apr;75(2):77-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral detachment prostatectomy using a tissue morcellator for large benign prostatic hyperplasia.
  • OBJECTIVE: Transurethral enucleation of the prostate (TUE) is designed for complete removal of the prostate lobes.
  • On the basis of TUE and holmium laser enucleation of the prostate, we developed a new technique of transurethral detachment prostatectomy (TUDP) using a tissue morcellator.
  • MATERIALS AND METHODS: In TUDP, enucleation is performed with a prostate-detaching blade and the tip of a resectoscope, followed by removal of the tissue with a morcellator.
  • This study reports our experience with TUDP in which the weight of retrieved tissue was greater than 30 g in 76 patients with benign prostate hyperplasia.
  • RESULTS: The mean preoperative total prostate and adenoma volumes were 70.7 and 47.4 mL, respectively.
  • The mean weight of removed prostate tissue was 61.1 g.
  • The mean preoperative maximum flow rate (Qmax), International Prostate Symptom Score (IPSS), and quality of life score (QOL) improved from 9.8 mL/sec, 20.2, and 4.9, to 22.3 mL/sec, 3.1 and 1.2, respectively.
  • The mean prostate volume and serum prostate-specific antigen level measured 6 months postoperatively in 46 patients were 10.68 mL and 0.89 ng/mL, respectively.
  • CONCLUSIONS: TUDP is effective for complete removal of large prostate lobes in patients with large benign prostate hyperplasia and is associated with lower perioperative morbidity.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Organ Size. Postoperative Complications. Prostate / pathology

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18475027.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Kumanov P, Nandipati KC, Tomova A, Robeva R, Agarwal A: Significance of inhibin in reproductive pathophysiology and current clinical applications. Reprod Biomed Online; 2005 Jun;10(6):786-812
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunoreactivity against the inhibin alpha-subunit was identified in all cases of adrenal cortical adenoma and carcinoma, and levels are suppressed in the malignant prostate disease.

  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970011.001).
  • [ISSN] 1472-6483
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Follistatin; 0 / alpha-Macroglobulins; 104625-48-1 / Activins; 57285-09-3 / Inhibins
  • [Number-of-references] 114
  •  go-up   go-down


83. Abdel-Khalek M, Sheir KZ, El-Baz M, Ibrahiem el-H: Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen &gt;10 ng/ml and prior negative peripheral zone biopsy? Scand J Urol Nephrol; 2005;39(1):49-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
  • OBJECTIVES: To evaluate the importance of transition zone (TZ) biopsy in benign prostatic hyperplasia (BPH) patients with serum prostate-specific antigen (PSA) >10 ng/ml and prior negative peripheral zone (PZ) biopsy and to estimate the sensitivity of TZ biopsy.
  • Overall, 215 patients were subjected to either transurethral resection of the prostate (n=162) or open enucleation of the adenoma (n=53).
  • RESULTS: The extended biopsy revealed prostate cancers in 21.2% of cases (58/273).
  • Prostate volume (p=0.023), TZ volume (p=0.027) and PSA/TZ density (p=0.007) were predictive of TZ cancers.
  • [MeSH-major] Biomarkers, Tumor / blood. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / pathology
  • [MeSH-minor] Aged. Biopsy. Humans. Incidence. Male. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / epidemiology. Sensitivity and Specificity


84. Takiuchi H, Nakao A, Ihara H: [Prevention of transient urinary incontinence in peri-operative period of modified holmium laser enucleation of the prostate (HoLEP)]. Hinyokika Kiyo; 2008 Jul;54(7):475-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevention of transient urinary incontinence in peri-operative period of modified holmium laser enucleation of the prostate (HoLEP)].
  • From February 2005 to April 2007, 48 consecutive patients with BPH underwent holmium laser enucleation of the prostate (HoLEP) combined with mechanical morcellation.
  • In the latter 17 consecutive cases (group 3), we used a modified HoLEP procedure, which partially preserved the apical adenoma in the 10-to 2-o'clock position.
  • International Prostate Symptom Score, quality of life index, urinary flow (Qmax) data, and postvoid residual urine were significantly improved postoperatively in each group, there being no differences among them with the exception that group 3 had better Qmax data than group 3 at one month after operation.
  • [MeSH-major] Holmium / therapeutic use. Lasers, Solid-State / therapeutic use. Postoperative Complications / prevention & control. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Urinary Incontinence / prevention & control


85. Hansel DE, Nadasdy T, Epstein JI: Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma.
  • Nephrogenic adenomas demonstrate a variety of morphologic patterns that may occasionally be confused with malignant processes, including urothelial and prostatic carcinoma.
  • In this series, we describe 8 cases of nephrogenic adenoma that contain an admixture of the classic tubular form of nephrogenic adenoma and an unusual spindled and fibromyxoid form of nephrogenic adenoma that closely mimics infiltrating carcinoma.
  • In all cases, the classic tubular form of nephrogenic adenoma composed only a small proportion of the lesion, whereas the remainder consisted of compressed spindled cells within a fibromyxoid background, with only rare tubular and cordlike structures.
  • All 8 patients were elderly men who had a prior or concurrent history of acinar prostate cancer (n=4), combined acinar prostate and urothelial carcinoma (n=1), urothelial-type adenocarcinoma of the prostate (n=1), bladder urothelial carcinoma (n=1), or no prior reported prostatic or urothelial abnormalities (n=1).
  • Immunostains for prostate-specific antigen were negative.
  • This case series is the first report of a fibromyxoid subtype of nephrogenic adenoma.
  • Awareness of this entity and the use of ancillary techniques can aid in the diagnosis of this unusual form of nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Fibroma / pathology. Urologic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Middle Aged. Mucins / analysis. Neoplasms, Multiple Primary. Urothelium / chemistry. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667548.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


86. Shimizu Y, Hiraoka Y, Iwamoto K, Takahashi H, Abe H: Measurement of residual adenoma after transurethral resection of the prostate by transurethral enucleation technique. Urol Int; 2005;74(2):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of residual adenoma after transurethral resection of the prostate by transurethral enucleation technique.
  • OBJECTIVE: Transurethral resection of the prostate (TURP) leaves a lot of residual adenoma and has a high recurrence rate, but the residual adenoma weight has not been measured surgically.
  • Using surgery we tried to measure the residual adenoma after TURP.
  • MATERIAL AND METHODS: Total adenoma resection was performed via standard TURP in 64 cases with benign prostatic hyperplasia and the weight of the residual adenoma was measured by transurethral enucleation (TUE) of the prostate.
  • RESULTS: Prostate volume averaged 37.4 ml and adenoma volume averaged 20.6 ml by TRUS.
  • The average weight of the prostate removed by TURP was 9.8 g.
  • After TURP residual adenoma was confirmed in all cases by TUE, and the average weight of the residual adenoma was 10.2 g.
  • The total average prostate volume removed by TURP and TUE was 20.1 g.
  • The average residual rate of the adenoma removed by TURP was 54.5%.
  • CONCLUSION: TURP leaves about half of the adenoma.
  • Therefore, TURP might be very difficult for complete resection of an adenoma.
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756059.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


87. Cabello Benavente R, Jara Rascón J, Monzó JI, López Díez I, Subirá Ríos D, Lledó García E, Herranz Amo F, Hernández Fernández C: [Volume determinations of the whole prostate and of the adenoma by transrectal ultrasound: correlation with surgical specimen]. Actas Urol Esp; 2006 Feb;30(2):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Volume determinations of the whole prostate and of the adenoma by transrectal ultrasound: correlation with surgical specimen].
  • [Transliterated title] Correlación ecográfico-anatómica de la medición del volumen prostático total y de la zona transicional mediante ecografía transrectal.
  • OBJECTIVE: We evaluated whether preoperative transrecta ultrasound (TRUS) mesaurements of the transition zone (TZ) and total prostate volumen predict real prostatic weight.
  • MATERIAL AND METHODS: We compare estimated TRUS volumes with surgical specimen weight, in surgically treated patients with localized prostate cancer (group A, n = 33) or benign prostatic hyperplasia (group B, n = 37).
  • Both measurements were compared with surgical specimen weight, assuming 1 as specific prostate weight.
  • RESULTS: Group A: mean prostate measured volume was 38.6 cc. (SD 22.7), mean RP specimen weight was 54,2 g (SD 27.2) (p = 0.001).
  • Total estimated prostate volume underestimated prostatectomy specimen weight by 29%.
  • In order to adequate the estimated volume to the specimen weight, we calculated the formula: estimated prostate weight = 0.95 x prostatic measured volume + 17,657 (p = 0.005).
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / ultrasonography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700208.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


88. Mustafaev EM, Martov AG, Naumov AG, Siniukhin VN, Shakir F, Merinov DS, Amelin AV, Al'bitskaia AIu: [The role of ozone therapy in prevention of pyoinflammatory complications after transurethral resection of prostatic adenoma]. Urologiia; 2007 Jan-Feb;(1):18-23, 27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of ozone therapy in prevention of pyoinflammatory complications after transurethral resection of prostatic adenoma].
  • The study of efficacy of ozone therapy (OT) in preparation of patients with prostatic adenoma (PA) and cystostoma for transurethral resection (TUR) of PA included 20 PA patients with cystostomic drainage who had undergone PA TUR and preoperative preparation with OT sessions.
  • OT efficacy was assessed by the rate of pyoinflammatory complications (PIC), results of immunological examination, positive changes in prostatic secretion, urine analysis, total blood count, degree ofbacteriuria.
  • Mean control count of leukocytes in prostatic secretion fell in both groups.
  • [MeSH-major] Ozone / therapeutic use. Physical Therapy Modalities. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatitis / prevention & control. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Ozone.
  • Hazardous Substances Data Bank. OZONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471993.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 66H7ZZK23N / Ozone
  •  go-up   go-down


89. Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG: [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy]. Urologiia; 2007 Mar-Apr;(2):80-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy].
  • [MeSH-major] Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Serenoa / chemistry

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578203.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts
  • [Number-of-references] 33
  •  go-up   go-down


90. Baker SG, Kramer BS: Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests. J Med Screen; 2008;15(1):18-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The method is illustrated with data from the screening arm of the randomized Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
  • With an FP defined as a diagnostic work-up in the absence of cancer (or advanced adenoma) within three years, the probability of at least one FP among 14 tests in men was 60.5% with 95% confidence interval of (59.3%, 61.6%).
  • [MeSH-major] Mass Screening / methods. Neoplasms / diagnosis


91. Sitdykova ME, Zubkov AIu: [Efficacy of vitaprost forte in the treatment of prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in the treatment of prostatic adenoma].
  • Thirty patients with a documented diagnosis of prostatic adenoma were treated with vitaprost forte (100 mg rectal suppositoria) for 60 days.
  • Its efficacy was proved by improved urodynamics of the lower urinary tract, reduction of prostatic size.
  • Vitaprost forte is recommended for treatment of patients suffering from prostatic adenoma with mild and moderate symptoms.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169719.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


92. Miariatskas G, Aliakna V, Cheremnykh E: [Prevalence of enuresis in old males according to questionnaire data]. Urologiia; 2007 Mar-Apr;(2):21-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk to develop continuous incontinence grows in the presence of Parkinson's disease (OR = 3.50; 95% CI = 1.01-12.23), prostatic adenoma (OR = 5.29; 95% CL = 2.91-9.65).

  • MedlinePlus Health Information. consumer health - Bedwetting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578196.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


93. Pantuck AJ, Baniel J, Kirkali Z, Klatte T, Zomorodian N, Yossepowitch O, Belldegrun AS: A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol; 2007 Dec;178(6):2331-6; discussion 2336
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel resectoscope for transurethral resection of bladder tumors and the prostate.
  • Transurethral prostate resection may be complicated by inadvertent damage to the urinary sphincter, bladder neck and trigone.
  • It consists of variably sized cutting loops designed for transurethral resection of bladder tumors and the prostate.
  • To date 80 patients with bladder cancer (38) or benign prostatic hyperplasia (42) have undergone surgery with this instrument at our 3 clinical sites.
  • During transurethral prostate resection this novel tool facilitated dissection of adenoma adjacent to the verumontanum and prostatovesical junction, which may decrease the risk of sphincteric damage and bladder neck injury.
  • Current data suggest that the learning curve is mild, its use is safe and it provides distinct advantages when used for transurethral resection of bladder tumors and the prostate.
  • [MeSH-major] Endoscopes. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Transurethral Resection of Prostate / instrumentation. Urinary Bladder Neoplasms / surgery


94. Mathers JC: Folate intake and bowel cancer risk. Genes Nutr; 2009 Sep;4(3):173-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, human intervention studies using relatively large doses (500-5,000 mug/day) of folic acid (a synthetic form of folate) have provided no evidence of benefit in terms of adenoma recurrence.
  • Indeed, there is some evidence of potential harm in increased risk of prostate cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2409-15 [18768511.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3254-66 [18597513.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2828-38 [18539961.001]
  • [Cites] Br J Nutr. 2008 Mar;99(3):550-8 [17868491.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):29-38 [18022173.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2128-35 [17932361.001]
  • [Cites] Br J Nutr. 2007 Oct;98(4):667-75 [17617936.001]
  • [Cites] J Cell Sci. 2007 Oct 1;120(Pt 19):3327-35 [17881494.001]
  • [Cites] J Nutr. 2007 Sep;137(9):2114-20 [17709451.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1325-9 [17626997.001]
  • [Cites] BMC Public Health. 2007;7:41 [17378936.001]
  • [Cites] J Nutr. 2006 Dec;136(12):3015-21 [17116713.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1567-77 [16531613.001]
  • [Cites] J Nutr. 2006 Jan;136(1):189-94 [16365081.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] Am J Clin Nutr. 2005 Aug;82(2):442-50 [16087991.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):825-8 [15499620.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2004 Nov;70(11):844-5 [15468072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3290-5 [9096386.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1098-102 [9067278.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):423-43 [14977639.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • [Cites] Am J Clin Nutr. 2008 Sep;88(3):763-8 [18779294.001]
  • (PMID = 19499262.001).
  • [ISSN] 1555-8932
  • [Journal-full-title] Genes & nutrition
  • [ISO-abbreviation] Genes Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2745742
  •  go-up   go-down


95. Dixon LB, Subar AF, Peters U, Weissfeld JL, Bresalier RS, Risch A, Schatzkin A, Hayes RB: Adherence to the USDA Food Guide, DASH Eating Plan, and Mediterranean dietary pattern reduces risk of colorectal adenoma. J Nutr; 2007 Nov;137(11):2443-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adherence to the USDA Food Guide, DASH Eating Plan, and Mediterranean dietary pattern reduces risk of colorectal adenoma.
  • Our objective was to determine whether adherence to the USDA Food Guide recommendations, the DASH Eating Plan, or a Mediterranean dietary pattern is associated with reduced risk of distal colorectal adenoma.
  • In the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, men and women aged 55-74 y were screened for colorectal cancer by sigmoidoscopy at 10 centers in the U.S.
  • After adjusting for potential confounders, men who most complied with the USDA Food Guide recommendations had a 26% reduced risk of colorectal adenoma compared with men who least complied with the recommendations (OR USDA score >or= 5 vs. <or=2 = 0.74, 95% CI = 0.64-0.85; P-trend < 0.001).
  • Women who most complied with the USDA Food Guide recommendations had an 18% reduced risk for colorectal adenoma, but subgroup analyses revealed protective associations only for current smokers (OR USDA score >or= 5 vs. <or=2 = 0.52, 95% CI = 0.31-0.89; P-trend < 0.01) or normal-weight women (OR USDA score >or= 5 vs. <or=2 = 0.74, 95% CI = 0.55-0.99; P-trend = 0.08).
  • Following the current U.S. dietary recommendations or a Mediterranean dietary pattern is associated with reduced risk of colorectal adenoma, especially in men.
  • [MeSH-major] Adenoma / prevention & control. Colorectal Neoplasms / prevention & control. Diet. Diet, Mediterranean. United States Department of Agriculture

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951483.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


96. Aliaev IuG, Grigorian VA, Tsarichenko DG, Lokshin KL, Kharchilava RR: [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control]. Urologiia; 2006 May-Jun;(3):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control].
  • The aim of the study was to improve the results of transurethral prostatic resection (TUPR) by introduction of intraoperative transrectal ultrasonic investigation (TRUSI) and to determine topographic-anatomic features of the prostate, intraorgan relations of adenomatous nodes and surgical prostatic capsule on-line in TUPR.
  • A total of 64 patients with prostatic adenoma (PA) of the second degree aged 52-79 participated in the study.
  • The patients were divided into two study groups (15 patients with volume of the prostate 36.5-78.6 cm3 and 17 patients with prostate size 80-4-141.2 cm3) in which TRUSI was performed and two control groups (n = 14, size 34.9 to 79.2 cm3 and n = 18, size 81.7-130.8 cm3, respectively) who have not undergone intraoperative TRUSI.
  • Control TRUSI on day 7 after TUPR registered mean volume of the prostate to be 19.3 +/- 1.4 cm3 in group 1, 39.8 +/- 2.1 cm3 in group 2, 28.1 +/- 1.6 cm3 in group 3, 47.7 +/- 3.2 cm3 in group 4.
  • Thus, intraoperative TRUSI provides information which helps the surgeon to orient in the course of surgery and minimize the threat of perforation of the prostatic capsule; minimizes intraoperative complications and enhances efficacy of radical transurethral electroresection of prostatic hyperplasia improving long-term outcomes of the operation.
  • [MeSH-major] Intraoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Hyperplasia / ultrasonography. Transurethral Resection of Prostate. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889081.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


97. Mireku-Boateng AO, Jackson AG: Prostate fossa packing: a simple, quick and effective method of achieving hemostasis in suprapubic prostatectomy. Urol Int; 2005;74(2):180-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate fossa packing: a simple, quick and effective method of achieving hemostasis in suprapubic prostatectomy.
  • INTRODUCTION: Suprapubic prostatectomy remains a very common surgical treatment for bladder outlet obstruction from an enlarged prostate in the developing world.
  • We describe our experience with prostatic fossa packing at the time of the procedure, as a very simple, quick and effective technique for maximal hemostasis.
  • CONCLUSION: Packing of the prostatic fossa at the time of enucleation of the adenoma is a very simple, quick and effective way to achieve hemostasis in suprapubic prostatectomy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756072.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


98. Bensalah K, Fleureau J, Rolland D, Rioux-Leclercq N, Senhadji L, Lavastre O, Guillé F, Patard JJ, de Crevoisier R: [Optical spectroscopy: a new approach to assess urological tumors]. Prog Urol; 2010 Jul;20(7):477-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La spectroscopie optique : une nouvelle approche pour l'étude des tumeurs urologiques.
  • Several publications specifically aimed at assessing prostate cancers, renal carcinomas and urothelial tumors.
  • Optical spectroscopy can differentiate benign (adenoma or inflammation) and malignant (adenocarcinoma) prostatic tissues.
  • Regarding renal tumors, spectroscopy can identify normal and tumoral tissue and differentiate benign and malignant tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20656268.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  •  go-up   go-down


99. Babyatsky M, Lin J, Yio X, Chen A, Zhang JY, Zheng Y, Twyman C, Bao X, Schwartz M, Thung S, Lawrence Werther J, Itzkowitz S: Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis; 2009;26(2):143-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trefoil factor-3 (TFF3) is expressed by normal intestinal epithelial cells and its expression is maintained throughout the colon adenoma-carcinoma sequence.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Endocrinol Metab. 2008 Mar;19(2):74-81 [18054496.001]
  • [Cites] Glycoconj J. 2001 Nov-Dec;18(11-12):871-82 [12820721.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12 (26):4143-8 [16830362.001]
  • [Cites] Regul Pept. 2005 Apr 15;127(1-3):87-94 [15680474.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4036-44 [8033134.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):489-97 [8566596.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):375-9 [1985035.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1092-9 [12006524.001]
  • [Cites] Genomics. 2003 Jul;82(1):78-85 [12809678.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] J Pathol. 1997 Sep;183(1):30-8 [9370944.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1125-31 [9737246.001]
  • [Cites] Cell Tissue Res. 2001 Jan;303(1):109-15 [11235998.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7405-12 [16437709.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):60-9 [10611154.001]
  • [Cites] FASEB J. 1996 Nov;10 (13):1518-23 [8940297.001]
  • [Cites] J Cell Biol. 1979 Feb;80(2):248-65 [88453.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):12-20 [8419234.001]
  • [Cites] Endocrinology. 2006 Dec;147(12 ):5752-9 [16973727.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):509-15 [10821500.001]
  • [Cites] Clin Exp Metastasis. 2005;22(2):157-65 [16086236.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Endocr J. 2009;56(1):9-16 [18506086.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):932-4 [9462243.001]
  • [Cites] J Clin Invest. 2002 Jan;109 (2):193-204 [11805131.001]
  • [Cites] Annu Rev Physiol. 1996;58:253-73 [8815795.001]
  • [Cites] Acta Otolaryngol. 2001 Oct;121(7):849-53 [11718251.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6472-8 [16166422.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Sep;4(9):721-32 [14506475.001]
  • [Cites] J Histochem Cytochem. 2007 May;55(5):505-13 [17242463.001]
  • [Cites] J Pathol. 2007 Jul;212(3):278-86 [17471475.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9353-61 [7721858.001]
  • [Cites] Genomics. 1997 Feb 15;40(1):200-2 [9070946.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1330-5 [10194185.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1171-85 [12368191.001]
  • [Cites] J Biol Chem. 1993 Mar 25;268(9):6694-702 [8454642.001]
  • [Cites] Life Sci. 2005 Apr 15;76(22):2581-92 [15769482.001]
  • [Cites] FEBS Lett. 1989 Jun 19;250(1):85-90 [2737304.001]
  • [Cites] J Pathol. 1997 Sep;183(1):4-7 [9370940.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(13):4680-90 [10848594.001]
  • [Cites] FASEB J. 2001 Feb;15(2):351-61 [11156951.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):397-408 [11310832.001]
  • [Cites] J Clin Invest. 1994 Jul;94(1):376-83 [8040278.001]
  • [Cites] Lab Invest. 1996 Jul;75(1):25-32 [8683937.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):369-77 [15645121.001]
  • [Cites] J Pathol. 1997 Aug;182(4):404-13 [9306961.001]
  • [Cites] J Pathol. 2002 Aug;197(5):582-8 [12210076.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):655-9 [12168114.001]
  • (PMID = 18979216.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA109189
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / Peptides; 0 / TFF3 protein, human; 0 / TFF3 protein, rat; 0 / Trefoil Factor-3
  •  go-up   go-down


100. Elhilali M: Editorial comment. Urology; 2010 Dec;76(6):1455-6; author reply 1456
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / surgery. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Urinary Incontinence, Stress / prevention & control
  • [MeSH-minor] Aged. Dissection / methods. Hemostasis, Surgical. Humans. Male. Middle Aged. Organ Size. Prostate / pathology






Advertisement